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The majority of GWAS (Genome-Wide Association Study) identified common 
genetic variants map to regulatory regions of gene, and are likely to influence disease risk 
by affecting gene expression. One of the most important challenges is to experimentally 
fine-map causal regulatory variants that typically lie in credible intervals of 100 or more 
variants. Another large proportion of genetic variants, rare variants, are expected to have 
large effects causing disease in individual, but are not detectable in GWAS. Herein, I 
provide both experimental and computational approaches for fine-mapping common and 
rare genetic variants accounting for medium and large effect on population or individual. 
First, I describe a single cell clone-based strategy for targeted single-nucleotide 
polymorphism (SNP) evaluation wherein microindels are introduced by CRISPR/Cas9. 
Multiple constraints, including the variability in mutability, clonal genotype and expense, 
render this approach infeasible for fine-mapping 10%-20% moderate effect size expression 
SNPs (eSNPs), which is also validated in a simulation study. Subsequently, I switch to a 
moderate-throughput parallel screening tool that characterizes multiplexed CRISPR/Cas9 
perturbed transcriptomes by single-cell RNA-seq, called “expression CROP-seq”. Two 
causal SNPs, rs2251039 and rs35675666, are identified that significantly alter the 
expression of CISD1 and PARK7, respectively. The sites overlap with chromatin 
accessibility peaks and are risk loci of inflammatory bowel disease. Expression CROP-seq 
reduces the variability identified in previous method and is powerful to screen genetic 
regulatory variants within credible intervals. Finally, to extend its application to rare 
variants, I develop a novel gene categorization system according to gene intolerance to 
promoter polymorphism and depletion of rare regulatory variants with GTEx v8 data. 49 
xiv 
 
GTEx tissues are clustered into functional groups with gene features. It supports the use of 
tissue-gene genomic annotation for prioritization of GWAS tagged risk loci. In summary, 
this work comprehensively describes and evaluates two CRISPR/Cas9-based eSNP 
screening systems. The use of rare regulatory variants in gene classification with tissue 
information demonstrates its potential in rare disease diagnoses. Both researches inevitably 
contribute to the genetic interpretation of human complex disease and personalized 
medicine in post-GWAS era. 
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CHAPTER 1. INTRODUCTION 
1.1 Genome-wide association study (GWAS) 
Since completion of the human genome project in 20031, millions of SNPs have been 
found throughout the human genome. With the implementation of SNP genotyping, 
scientific questions concerning the extent of correlation between SNPs and common 
diseases or quantitative traits have been addressed. GWAS, namely genome wide study of 
the association of genotypes with disease status or traits, was first reported in 2005. The 
first GWAS study was conducted with 96 cases and 50 controls using 116,204 genotyped 
SNPs, and found an intronic and common variant in the CFH gene strongly associated with 
age-related macular degeneration (AMD), which increased likelihood by 7.4 in individuals 
homozygous for the risk allele2. One year later, two follow-up studies3,4 found another risk 
locus in HTRA1 for AMD, and a promoter region SNP rs11200638 was identified as the 
causal variant.  
In general, GWAS detects common variants with small odds ratios (from 1.2 to 2), 
thousands of which each explain of the order of 0.1% of common disease risk5. The most 
well-known GWAS study was published in 2007 from the Wellcome Trust Case Control 
Consortium, WTCCC, which examined 14,000 cases and 3,000 controls for 7 common 
diseases, and found 58 risk loci6. Subsequently, the publication of GWA studies has been 
increasing dramatically. As of February 2020, 172,351 associations have been collated in 
the GWAS catalog (https://www.ebi.ac.uk/gwas/).  
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Figure 1.1 SNP-trait associations with p-value ≤ 5.0 × 10-8, published in the GWAS 
Catalog (as of Feb, 2020). 
Investments are now being made in post-GWAS functional characterization.  First, fine-
mapping. GWAS mostly discovers tagging SNPs only, and the identity of the causal SNP 
remains unknown. A possible reason is the linkage disequilibrium (LD) of genome. Linkage 
disequilibrium is the non-random alleles association between loci in the same chromosome or 
at different chromosome. And different population have distinct LD structures. The LD 
structure is a confounding factor for identifying causal variant in GWAS, but it also helps to 
efficiently design a small fraction of markers genotyped without actually obtaining whole 
genome sequences. Targeted resequencing the region surrounding tagging SNPs makes it 
possible to refine the list of candidate causal SNPs. For example, deep next generation 
resequencing of 56 associated risk loci of inflammatory bowel disease (IBD) identified 
additional new, rare and probably functional variants in 8 genes7. Second, integration of 
functional regulatory data. Most of the GWAS-identified tagging SNPs are located in 
regulatory regions, such as enhancer and promoters. Functional genomics data integration, 
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including DNase sensitivity, histone modification and epigenetics, is an efficient approach to 
prioritize causal variants and also provide functional interpretation of GWAS identified SNPs. 
Third, expression quantitative trait loci, eQTL. These are genomic loci associated with gene 
expression. Since GWAS tagging SNPs sometimes overlap with eQTL signals, studying eQTL 
is a straightforward way to study disease and phenotype association. Moreover, another 
advantage of eQTL study is that it requires smaller sample sizes to achieve sufficient power. 
eQTLs tend to explain more expression variation than GWAS SNPs, because their effect size 
is much higher. Furthermore, eQTL studies can be easily performed in cell lines, primary cells 
and tissues. eQTL will be discussed further in the following section.   
1.2 eQTL 
An eQTL is a locus that explains a significant proportion of the variation in the transcript 
abundance of a gene. eQTLs are classified as cis-eQTLs and trans-eQTLs. cis-eQTLs are 
typically defined as being located within 1Mb from either side of transcription start sites (TSS), 
and trans-eQTLs are located farther than 5Mb from the TSS, or on another chromosome8. 
Discovery of cis-eQTL has a much higher yield than trans-eQTL because they tend to explain 
considerably more variation9, most likely because they directly regulate expression of the 
nearby gene10.  
For human eQTL mapping, the gene expression data is mostly from peripheral blood, 
since it is the most accessible tissue. However, some eQTLs are cell-type specific, tissue-
specific and context-dependent, so discovering eQTL only from blood is not sufficient to 
uncover their relationship to disease. Dimas et.al.11 conducted cis-eQTL analysis on 75 
individuals for three cell types, primary fibroblasts, lymphoblastoid cell lines and T cells, and 
found that 79.5% of the eQTLs were cell-type specific. This early study implied that only 20% 
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of the eQTL were shared either by two or three cell types, but subsequent work has gradually 
increased that percentage. Several other research groups have purified various subsets of 
peripheral blood cells.  For example, a comparison of naïve T CD4+ cells and monocytes using 
RNA sequencing, showed that disease and trait-associated cis-eQTLs display more cell 
specificity than on average: 46% were monocyte-specific, 29% were T cell-specific and 25% 
were shared12. On the other hand, CD4+ and CD8+ T-cells share the vast majority of eQTL13, 
with some functionally important exceptions, and enrichment studies are likely to highlight 
which cell types mediate which diseases.  
Initiated in 2013, the Genotype-Tissue Expression (GTEx) project has provided insights 
into the correlation between genotype and tissue-specific gene expression from autopsies of 
recently deceased individuals14. The most recent GTEx v8 data reports 17,382 RNA-
sequencing samples from 54 tissues of 948 post-mortem donors, 838 out of which also have 
genotypes available, mostly from whole genome sequencing15.  There are 18,262 protein-
coding eGenes (94.7% of all eGenes) discovered with at least one eSNP in at least one tissue 
and 4,278,636 genetic cis-eQTL. The tissue-specific eQTLs are either highly tissue-specific or 
highly shared across tissues.  
1.3 CRISPR/Cas9 genome editing  
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas is an 
adaptive immune system in bacteria and archaea16 that has been bioengineered into a genome 
editing tool. Jennifer Doudna and colleagues first showed that it is possible for the 
endonuclease cas9 to cleave targeted genomic DNA in vitro when guided to the site by a guide 
RNA (sgRNA)17. Around about the same time, Feng Zhang and colleagues first reported the 
application of a CRISPR/Cas system in human cell lines and mice cell lines for efficient and 
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precise editing of the genome18. This RNA-guided genome editing tool has since been widely 
used in bacteria19, yeast20, zebrafish21, mice22 and plants23. The mechanism of this technology 
is that Cas9 nuclease introduces a double-stranded break in the targeted site under the guidance 
of the sgRNA. Then, two potential DNA repair pathways, either nonhomologous end joining 
(NHEJ) or homology-directed repair (HDR), are engaged in the repair process. In the absence 
of a repair template, NHEJ is activated, which introduces unpredictable patterns of insertions 
and deletions near the edited site. This reaction can reach high editing efficiency up to 20%-
60%24. With the introduction of template, HDR is activated to precisely replace the target site 
with the exogenous template DNA, but the editing efficiency is only 0.5%-20%.  
Off-target effects, where cleavage is observed at a similar sequence elsewhere in the 
genome, are common in human cell lines. The CRISPR/Cas9 system can be highly active even 
where fives mismatches occur in the off-target site25. This is not random and can be predicted 
to some extent in silico26-28. The research group of Gang Bao at Rice University have developed 
a web interface software COSMID (CRISPR Off-target Sites with Mismatches, Insertions, and 
Deletions), which predicts the potential off-target sites26. Based on input guide RNA sequence, 
COSMID identifies potential off-target sites through the genome with specified number of 
mismatched bases and insertions or deletions.  
1.4 Experimental approaches for screening regulatory elements 
1.4.1 Massively parallel reporter assays (MPRA) 
Massively parallel reporter assays couple short segments of potentially regulatory 
DNA to barcodes which are transcribed following transfection into cells or animals. An 
invariant promoter-ORF (open reading frame) segment is inserted between the screened 
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variants and barcode. Sequencing approaches allow identification of under- or over-
represented barcodes indicating differential expression due for example to polymorphisms 
(Figure 1.2). 
MPRA has been applied to investigate the transcriptional regulation rules in yeast29. 
A fluorescence reporter based MPRA was used to systematically survey 6,500 yeast 
promoters’ for regulatory activity, thereby documenting the effects on gene expression of 
binding-site location, number, orientation and affinity.  Soon after this study, the 
application on human enhancer screening was reported30. This group tested 2,104 wild type 
enhancers and 3,314 mutated enhancers with disrupted motifs in K562 and HepG2 cell 
lines. They found that enhancer activity is cell-type specific and that predicted activator 
motifs and evolutionary conserved motifs can be used to predict enhancer activity.  
The application of MPRA for mapping genetic variants down to single nucleotide 
level has been reported. The screening scale ranges from tens to hundreds and up to 
millions of variants. Tewhey et. al31,  first screened 79,000 single nucleotide variants 
(single-nucleotide and small insertion/deletion of both alleles) in two lymphoblastoid cell 
lines, NA12878 and NA19239, and HepG2 cells. They then used a refined screening library 
with 7,500 variants replicating the positive signals from the first trail. 852 variants showed 
differential expression between alleles, most of which were clustered near the lead eQTL 
and GWAS SNP, in regions of high so-called linkage disequilibrium. The limitation of this 
approach is that it can only detect regulatory activity leading to increased expression since 
baseline expression is typically low, but it can reach a resolution of 3 positive signals in 
one eQTL credible interval. MPRA alone is not an efficient tool with which to identify the 
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causal variants of disease or eQTL. CRISPR/Cas9 based genome editing experiments in 
cells and animals are need for further functional validation.  
Another large scale regulatory screening was conducted by modified MPRA with 
5.9 million SNPs, 57% of which are common variants, in K562 and HepG2 cell lines, called 
the survey of regulatory elements (SuRE)32. The identified variants that caused differential 
expression are called reporter assay QTL (raQTL), and approximately 20,000 were 
identified in each tested cell line. Most of raQTLs are enriched in promoter, enhancer and 
DNA hypersensitive sites, and they are likely to change expression by altering transcription 
factor binding affinity. The identified raQTLs were particularly useful when integrated 
with functional data alongside GWAS signals to prioritize disease risk variants.  
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Figure 1.2 Schematic of MPRA33. Open reading frame (ORF) is inserted into elements 
of interest and coupled barcodes. The construct library is transfected into a population of 
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cultured cells. The ratio of mRNA counts over plasmid counts quantified by deep 
sequencing can be used to infer the element regulatory activity.  
1.4.2 CRISPR/Cas9 based bulk cell screening  
There are two major approaches to screening of regulatory variants with 
CRISPR/Cas9 genome editing or CRISPRi functional genome inhibition. One is 
sequencing of barcodes of libraries of guide RNA from bulk cellular populations, assaying 
for enrichment or depletion of guide RNAs that target elements required for driving 
transcription. Another one is parallel perturbation of regulatory variants with a pool of 
guide RNAs in a library, then quantifying the target gene expression at single-cell 
resolution by single-cell RNA-seq. I will discuss the second strategy in the next subsection.  
Feng Zhang group34 CRISPRed comprehensively across 100kb regions  5’ and 3’ 
of the NF1, NF2 and CUL3 genes, selecting for loss-of-mutations that resulted in 
vemurafenib resistance in a BRAF-mutated human melanoma cell line A375. Each cell had 
been mutagenized with one guide RNA. The sgRNA count differential measured by deep 
sequencing between cells treated with and without vemurafenib was used as the bulk output 
measurement of which guides led to resistance. A similar approach named multiplexed 
editing regulatory assay (MERA) was used to tile thousands of mutations across 40 kb of 
the cis-regulatory region of four stem cell-specific genes35.  Furthermore, regulatory 
elements screening is not limited to the single gene-level, since it has also been expanded 
to the genomic wide scale by massively parallel tiling of binding sites.  Such screening of  
transcription factor binding sites for two genes has been reported in two different 
studies36,37: one of transcription factor p53 and ERα binding sites, and the other of FOXA1 
and CTCF binding sites, measuring gRNA counts in a breast cancer cell line.   
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Recent CRISPRi and CRISPRa pooled inhibition and activation screening assays 
utilize modified Cas9 proteins that bind to but do not cut the target site. They have enabled 
high-throughput screening of genomic elements influencing transcription38. Although this 
study perturbed 5,920 human candidate enhancers with dCas9, each cell had on average 20 
multiplex perturbations, increasing statistical power but potentially increasing off-target 
effects. Adapting the eQTL analysis framework, they described 664 cis-enhancer 
localization events, but this approach does not fine-map regulatory polymorphisms.  
1.4.3 CRISPR/Cas9 based single-cell RNA sequencing  
Five publications to date have described related methods using single cell RNAseq 
(scRNA-seq) as the read-out of pools of cells genetically perturbed via lentiviral CRISPR.  
The methods are known as Perturb-seq39,40, CRISP-seq41, CROP-seq42, and Mosaic-seq43. 
The primary idea is that each individual cell is paired with a lentiviral vector which 
is assumed to have disrupted the target of the gRNA it carries. The lentiviral vector is a 
third-generation lentiviral vector that contains two expression cassettes: one is an RNA 
polymerase II-driven guide barcode (GBC), the other is an RNA polymerase III driven-
gRNA expression cassette. Each gRNA is labeled with a guide barcode. During the step of 
single cell cDNA generation, each cell is encapsulated with beads as in regular scRNA-seq 
so that each cell is labeled with a cell barcode, and each transcript is labeled with a unique 
molecular identifier, or UMI. All of the transcripts are pooled together during the 
sequencing stage, and can be demultiplexed computationally by the identification of the 
three levels of barcodes, which are also sequenced. In CROP-seq42 (Figure 1.3), the lenti-
construct incorporates the gRNA cassette into the 3’-LTR region. During lentiviral 
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integration, the gRNA cassette is copied so that both the gRNA and barcode can be 
transcribed into small RNAs, one of which receives a polyA tail and can then be sequenced. 
In this way, the gRNA is sequenced without adding a guide barcode. Guide RNA pools 
have been reported targeting genes or enhancer regions, but there are no reports using guide 
RNA to target specific variants in non-coding regions within eQTL credible intervals.  
 
Figure 1.3 CROP-seq lentiviral construct42 
1.5 Rare variants  
Geneticists aim to explain the etiology of diseases in terms of identified effects of 
individual genetic variants, which include single-nucleotide polymorphism (SNP) and copy 
number variation. And each variant can be measured by risk allele frequency in the population 
and the effect size is typically described as an odds ratio. The product of the risk allele 
frequency and effect size determines the amount of variance explained in the population, and 
hence the statistical power to identify the causality of the variant. The higher the risk allele 
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frequency, or effect size, the higher the statistical power. Most interest and studies focus on the 
identification of associations for genetic variants between the diagonal dotted lines in Figure 
1.4, namely common variants with small effect size, rare variants with large effect size and 
intermediate alleles with moderate effect size. GWAS as discussed in section 1.1 is powerful 
to identify the association between common variants with common diseases or traits. Most 
GWAS-identified risk loci only explain a small proportion of the heritability. For example, 18 
identified risk loci for type two diabetes only account for 6% of the heritability44; 20% of the 
total heritability is explained by 32 identified risk loci associated with Crohn’s disease. A major 
challenge for the field is to reduce GWAS intervals to individual causal variants as this will 
illuminate mechanisms, and improve the development of polygenic risk scores.  
 
Figure 1.4 Genetic variants classified by allele frequency and effect size. The most 
investigated variants are in the parallel diagonal lines.  
Rare mutations also make a major contribution to disease risk for individual people. 
However, rare variants cannot be detected in GWAS, due to the limited sample size of the 
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allele. For example, if we want to detect a rare variant with allele frequency 10-5 and with effect 
size one standard deviation unit, a sample size of more than one million would be required45. 
Such large sample sizes are hard to achieve. Furthermore, current GWAS genotyping arrays 
do not capture rare variants. Targeted sequencing, whole genome sequencing and family-based 
studies will help to uncover causal rare variants. Another hypothesis is called “synthetic 
association”46. When rare variants are in linkage disequilibrium with a GWAS tagging SNP, a 
“synthetic association” between the common variant and the phenotype can arise, even though 
it is not causal.  In this case, the effect size is usually underestimated, and the fact that different 
rare variants can be responsible in different cases is missed. Simulation studies shows that 
synthetic association is inevitable, and real cases such as hearing loss show how rare variants 
can be synthetically associated with common GWAS identified variants46. 
Indeed, some rare variants with very large effect sizes are thought to cause diseases. 
There are 350 million people worldwide who suffer from rare diseases, and about 7,000 
diseases are defined as rare in the United States. Most of the rare diseases are genetic, caused 
by a mutation in single gene, and thus are present at birth. 30% of children with rare diseases 
die before the age of five. Even though each single disease affects a small number of people, 
collectively the burden on individual patients, families and socioeconomics is tremendous. To 
raise public awareness for rare disease, the last Friday of February is observed as rare disease 
day. In addition, there are a large number, perhaps the majority, of rare variants with odds 
ratios at least 10 that nevertheless have low penetrance.  A ten-fold increase in risk for a disease 
present in 1 percent of the population still only affects 10% of carriers.  Mapping rare causal 
variants of this type, as well as Mendelian ones, is a major objective of contemporary genetics. 
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With the advent of next generation sequencing, the identification of causal genes, and 
description of mutation patterns affecting them, has progressed remarkably. Table 1.147 
summarizes eight rare neuropsychiatric conditions caused by rare copy number variation.  
Table 1.1 Disease association with CNVs (modified from Manolio et. al., 200947) 









Autism/IMR 16p11.2 De novo 
deletion 
600 1 × 10−4 1% 100 
Autism  16p11.2 Rare 
duplication 
600 3 × 10−4 0.50% 16 
Schizophrenia 1q21.1 Rare deletion 1,400 2 × 10−4 0.30% 15 
IMR 1q21.1 Rare deletion 1,400 2 × 10−4 0.47% NA 
Schizophrenia  15q13.3 Rare deletion 1,600 2 × 10−4 0.20% 12 
Epilepsy 15q13.3 Rare deletion 1,600 2 × 10−4 1.0% NA 
IMR 15q13.3 Rare deletion 1,600 2 × 10−4 0.30% NA 
Schizophrenia  22q11.2 Rare deletion 3,000 2.5 × 10−4 1% 40 
 
Apart from conventional diagnosis, molecular diagnosis has been developed with the 
implementation of next generation sequencing based approaches, whole-exome sequencing, 
whole-genome sequencing and targeted sequencing. Diagnostic yield for rare diseases is 
typically around 40% and it is important to achieve a higher diagnostic yield in infants. Whole 
exome sequencing diagnostic yield can be improved from 27% to 40% of children with 
developmental disorders48. Rapid whole genome sequencing, rWGS, improved diagnostic 
sensitivity to 43%, compared with 10% for standard genetic testing49. Ultra-rapid whole 
genome sequencing, urWGS, yields 46% diagnostic rate in infants with diseases of unknown 
etiology50. As a complementary molecular diagnostic tool, RNA sequencing shows success in 
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diseases that whole-exome sequencing fails, or improves diagnostics. For example, RNA-seq 
identifies splice-altering variants in both exonic and deep intronic regions, resulting in an 
overall diagnostic rate of 35% in a cohort of 50 patients with previously genetically 
undiagnosed rare muscle disorders51. Another study performed RNA sequencing of whole 
blood, which is the most easily accessible tissue. The cohort compromised 94 individuals with 
undiagnosed rare diseases spanning 16 disease categories. By analyzing gene expression levels 
and abnormal splicing, and combining these measures with variant identification, RNA-seq 
yielded a 7.5% diagnostic rate and 16.7% diagnostic improvement52.  
1.6 Thesis structure 
1.6.1 Specific aims: comprehensive identification of causal disease associated risk 
variants  
Over the past decade, tens of thousands disease/phenotype associated genetic risk 
loci have been identified by genome-wide association studies, but follow-up functional 
validation lags far behind.  The search for causal regulatory elements has become an 
important challenge for precise identification of causal risk loci. It is aided by the facts that 
most risk variants are located in noncoding regions, gene expression is a simple phenotype 
that is easy to measure in the lab, and regulatory variants often explain more variation than 
variants associated with visible traits. In this thesis, my primary goal was to develop a 
CRISPR/Cas9 based screening method to identify causal regulatory single nucleotides 
using RNA sequencing as the output measurement. I primarily focused on genes and SNPs 
that are also associated with autoimmune diseases since they are likely to be active in 
immune cell types sampled in blood or represented by human cell lines. Another objective 
was to work toward extending the strategy from common variants to rare variants, by 
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developing a rare variant pathogenic probability score. Such score should help to prioritize 
rare variants for experimental screening and facilitate personalized genome medicine.  
1.6.2 Aim 1: Establish a single-cell clone CRISPR/Cas9 based eQTL screening method  
Fine mapping refines statistical confidence intervals containing 100 and more SNPs 
to causal variants by integrating functional annotation. Two challenges are that it is hard to 
pinpoint one causal variant due to complex haplotype structure, and at least one third of all 
loci harbor multiple independent regulatory association signals. Therefore, experimental 
assays are needed to discriminate the effective SNP from the confounding remainder. In 
pursuit of this aim, in Chapter 2 I describe an NHEJ-based CRISPR/Cas9 single-cell clone 
assay for introducing microindels covering SNPs affecting CISD1, SDCCAG3, NFXL1 and 
AMFR expression. First, I characterized the transcriptomes of single-cell derived clones 
and neutrophil-, monocyte-differentiated HL60/S4 cells by RNA sequencing, quantifying 
biological variation among single-cell clones before and after induction of differentiation. 
Second, I tested the feasibility of the single-cell clone strategy by obtaining single-cell 
CRISPRed clones with introduced indels. Finally, I used the observed variance components 
to perform a statistical power computation under different simulated scenarios. After 
careful discussion of four major constraints, I concluded that this method is not 
recommended.  
1.6.3 Aim 2: Establish massively parallel eQTL screening with single-cell RNA-seq as 
readout 
  Subsequently, Aim 2 described in Chapter 3 switches the strategy to a single-cell 
RNA-seq based CRISPR/Cas9 pooling strategy, called expression CROP-seq. Single-cell 
 17 
RNA-seq robustly sequences thousands of cells in parallel, which reduces technical 
variation and captures individual cell variability at the same time. Infecting cells with 
gRNA library accomplishes moderate- to high-throughput genetic screening. Together 
these methods resolved the problems from aim 1, leading to report of a feasible method for 
moderate-throughput credible interval fine mapping I aimed to screen 57 eSNPs along with 
10 control, where each SNP was targeted by one gRNA. Approximately, 20 SNPs each 
were from credible intervals of DAP, CISD1 and PARK7, which have colocalized eQTL 
and IBD GWAS signals. I characterized the transcriptional profiles of thousands of single 
gRNA assigned cells in two biological replicates. The experiment was design to assign 
about 100 cells to each gRNA, and gRNAs were evenly distributed among engineered cells, 
except for those targeting two essential positive control genes. Two SNPs, rs2251039 and 
rs35675666, significantly reduced expression of the target genes CISD1 and PARK7, 
respectivelyin both replicates. Since ATAC-seq and DNase-seq peaks overlap with the two 
SNPs, and individual targeting confirmed the results, the proposed moderate-thought 
method is suitable to be used in screening of genetic variants with at least moderate effect 
size within credible intervals.  
1.6.4 Aim 3: Classification of the tolerance of promoter regions with the burden of rare 
variants across tissues 
  Rare variants are abundant in individuals. From an evolutionary perspective, large-
effect disease risk alleles should be rare under the pressure of purifying selection. A 
corollary is that ultra rare alleles often have large effects causing disease in individual. 
Thus, it is of high interest to extend the application of expression CROP-seq to rare 
regulatory variant screening.  In Chapter 4, I describe an approach that comprehensively 
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assigns rare variants a probability score that prioritizes which rare alleles are more likely 
to be pathogenic in a specific tissue. I tested whether the enrichment of rare variants in 
extreme expression individuals is common across 49 tissues with GTEx v8 data, and 
whether those rare alleles are depleted in genes that are intolerant to promoter region 
mutations. These results indicate that combining the relative promoter polymorphism and 
regulatory rare alleles accounting for large proportion of the variation in aberrant 
expression can be used for a gene categorization system.  
 In summary, the scope of this thesis is to provide both experimental and 
computational approaches to fine-map common and rare genetic variants accounting for 
medium and large effect to the population or individual. This reduces to massively parallel 
screening of regulatory SNPs within credible intervals and to pinpointing regulatory rare 
alleles with evolutionary intolerance of promoter region mutations across tissues.  
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CHAPTER 2. SINGLE CLONE CRISPR/CAS9 
MUTAGENESIS TO FINE-MAP REGULATORY 
INTERVALS 
ABSTRACT: The majority of genetic variants affecting complex traits map to regulatory 
regions of genes, and typically lie in credible intervals of 100 or more SNPs. Fine mapping 
of causal variant(s) at a locus depends on assays that are able to discriminate effects of 
polymorphisms or mutations on gene expression. Here we evaluate a moderate-throughput 
CRISPR/Cas9 mutagenesis approach based on replicated measurement of transcript 
abundance in single cell clones, by deleting candidate regulatory SNPs affecting 4 genes 
known to be affected by large-effect eQTL in leukocytes and using Fluidigm qRT-PCR to 
monitor gene expression in HL60 pro-myeloid human cells. We conclude that there are 
multiple constraints that render the approach generally infeasible for fine mapping. These 
include non-targetability of many regulatory SNPs, clonal variability of single cell 
derivatives, and expense. Power calculations based on the measured variance attributable 
to major sources of experimental error indicate that typical eQTL explaining 10% of the 
variation in expression of a gene would usually require at least 8 biological replicates of 
each clone. The above is published in Genes. This work was performed in collaboration 
with the group of Dr. Gang Bao, supervised by Dr. Ciaran Lee and with wet lab 
experiments performed by Dr. Yidan Pan at Rice University. My contribution was mostly 
the statistical analysis and writing of the paper, cell culture experiments and RNA-seq 
library preparation performed by me at Georgia Tech, along with input into experimental 
design. 
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2.1 Introduction  
Genome-wide association studies (GWAS) over the past decade have been highly 
successful in identifying tens of thousands of loci influencing disease risk45,53,54, but the 
fine mapping of causal variants has failed to keep pace. Exhaustive studies of Crohn’s 
disease and Type 2 diabetes associations, for example, indicate that the average credible 
interval size for hundreds of loci remains over 100 SNPs, and fewer than 15% of the loci 
have been reduced to a single high-confidence causal polymorphism55,56. This gap in 
knowledge impedes both the understanding of the biological functions of risk loci, and the 
progress in clinical genetic risk assessment. There are three main challenges to fine 
mapping. First, the haplotype structure of the human genome ensures that multiple SNPs 
lie in high linkage disequilibrium (LD) with the peak association signal, so that it is rarely 
possible to promote one variant as causal on statistical evidence alone. Second, it is now 
clear that at least one third of loci harbor multiple independent associations, most with 
overlapping credible intervals55-57. Third, the majority of the risk loci are located in non-
coding regions of genes58,59 where they exert their function through regulation of gene 
expression. Tools for predicting the function of such causal variants generally have low 
predictive value60,61.  
Moderate-to-high throughput methods are needed to prioritize likely causal variants 
by experimentally monitoring their effects on gene expression62. Two broad classes of 
approaches have been described: massively parallel reporter assays and genome editing. 
Massively parallel reporter assays couple short segments of potentially regulatory DNA to 
guide barcodes which are transcribed following transfection into cells or animals. 
Sequencing approaches allow identification of under- or over-represented barcodes 
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indicating differential expression due for example to polymorphisms. Genome editing 
approaches now most commonly use CRISPR/Cas9 to introduce short insertions, deletions 
and substitutions into targetable regions across the whole genome. RNA sequencing or 
other functional readouts such as fluorescence of a reporter gene, can be used to monitor 
the impact of specific variants. Recent CRISPRi and CRISPRa pooled screening assays 
utilize 52 catalytically dead/inactivated Cas9 enzymes (dCas9) that bind to but do not cut 
the target site. These 53 modified Cas9s have their endonuclease activity removed, but they 
are still able to bind to the target 54 sites where they contribute to inhibition or activation 
of gene expression via fused effector domains 55 such as KRAB (CRISPRi) and VP64 
(CRISPRa). They have enabled high-throughput screening of genomic elements 
influencing transcription38 and cellular phenotypes39-42 with single-cell transcriptome 
readout. However, the majority of these strategies screen regulatory intervals rather than 
individual SNPs, so are not appropriate for fine mapping causal variants.  
Here we evaluate the feasibility of gene-centric single cell clonal analysis, focusing 
on a handful of genes known to influence the risk of inflammatory bowel disease (IBD) 
through modulation of gene expression in immune cells. Specifically, we chose to examine 
four genes with evidence for two independent cis-eQTL intervals each, as well as GWAS-
significant associations with IBD. The CDGSH iron sulfur domain 1, CISD1, and 
serologically defined colon cancer antigen 3, SDCCAG3, genes are associated with both 
ulcerative colitis and Crohn’s disease63,64. The Autocrine Motility Factor Receptor, AMFR, 
encodes a glycosylated transmembrane receptor that is also an E3 ubiquitin ligase, 
knockdown of which in the acute monocytic leukemia cell line, THP-1, induces cell cycle 
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arrest and apoptosis, indicating a critical role for AMFR in cell proliferation65. NFXL1 is 
one of the most up-regulated genes in IL-4 induced macrophages66. 
We used an experimental strategy for targeted SNP evaluation wherein 
microdeletions targeting candidate eSNPs are introduced by CRISPR/Cas9, and then 
isolated as single-cell clones on a uniform genetic background. Although homology-
directed repair (HDR) would provide more precise evaluation of allelic replacement, the 
low efficiency relative to non-homologous end joining (NHEJ) and expectation that indels 
may have larger effects led us to use NHEJ in these experiments I chose the HL60 cell line, 
a pro-myelocytic lineage, which can be induced to undergo differentiation toward 
neutrophil- or monocyte-like fate, allowing evaluation of SNP effects in different cell 
types. Given the challenges in demonstrating conclusively the impacts of a single causal 
variant, we discuss sources of experimental variance encountered with this strategy, 
including batch, clonal and differentiation effects, and use these to derive realistic power 
estimates for dissection of causal variants. Comparing these estimates with empirically 
defined eQTL effect sizes, we conclude that this approach is generally incapable of 
resolving most regulatory associations to single causal variants.  
2.2 Materials and methods 
2.2.1 eGenes, candidate eSNPs and control SNP selection 
The eGenes CISD1 and SDCCAG3 were chosen due to the colocalization of eQTL 
signals and 85 associations with inflammatory bowel disease67. NFXL1 and AMFR were 
included as they are essential for myeloid cell differentiation. Candidate eSNPs were 
selected from one of at least two independent eQTL credible intervals at each locus 
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identified in a multiple eQTL study using stepwise conditional regression57 in two large 
peripheral blood microarray datasets, the Consortium for the Architecture of Gene 
Expression (CAGE)9 and Framingham Heart Study (FHS). They were also confirmed to 
be eQTL in monocytes68. It remains possible that they are not actually active in HL60 cells 
or their derivatives, and our experiments should be interpreted with this in mind. We also 
evaluated each SNP in the credible interval with Combined Annotation Dependent 
Depletion (CADD) score69 and evolutionary probability (EP)70. In each credible interval, 
we chose the SNP with the lowest p-value, named as “Top SNP”, SNPs with low 
evolutionary probabilities (EP) of the minor allele and (or) high CADD scores, named as 
“Both” and “High CADD”, respectively (Table 2.1). We also picked SNPs as negative 
controls with no eQTL signals and in linkage equilibrium with the top SNP, named as 
“Control”. Conditional eQTL profiles can be visualized using our eQTL Hub shiny browser 
at http://bloodqtlshiny.biosci.gatech.edu/. 
Table 2.1 Guide RNAs and target SNPs. Guide RNAs and target SNPs. Each guide 
RNA targets on the “SNP”, which is within a credible set of “gene”. The effect size (z-
score) of each SNP from the eQTLGen browser67. “Top SNP” is the SNP with lowest p-
value in the credible set. Several criteria was used to predict the likelihood of candidate 
SNPs: “High CADD” is the SNP with high CADD (Combined Annotation Dependent 
Depletion) score that has high level of deleteriousness of its variants, including Indel 
variants; “Top” is the SNP with strongest signal of eQTL-mapping; “Both” is the SNP 
with both high CADD score and low evolutionary probabilities (EP) of the minor allele; 
“Control” is the negative control SNP in high linkage disequilibrium (LD) with the top 
SNP but low CADD and normal EP. 
gRNA Gene Top SNP SNP z-score Type Genome location 
Coding 
region 
RG14 SDCCAG3 rs10870171 rs3812594 -34.60 High CADD 
Exon of 
SEC16A Yes 
RG16 CISD1 rs4397793 rs4397793 -23.84 Top Intron of TFAM No 
RG17 CISD1 rs4397793 rs648138 -70.54 Control Intergenic of TFAM No 
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RG19 CISD1 rs2590375 rs2590363 -100.37 Both Intron of IPMK No 
RG20 CISD1 rs2590375 rs1416763 -100.27 Both Intron of CISD1 No 
RG26 NFXL1 rs116521751 rs321622 -63.35 Both Intron of NIPAL1 No 
RG34 AMFR rs2550303 rs8060037 -14.09 Top Intron of NUDT21 No 
 
2.2.2 SNP-targeting and gRNA screening design 
The chromosomal position of each candidate SNP in reference genome hg19 was 
obtained from dbSNP71 by searching their RSID. The sequences flanking the targeted SNP 
were fetched from NCBI Reference Sequence (RefSeq), providing a gRNA screening 
window72. In each window, all the 19-base sequences followed by the correct S. pyogenes 
Cas9 Protospacer Adjacent Motif (PAM) sequence (NGG) were collected as candidate 
gRNAs. gRNAs with GC rate over 80% or less than 10% were filtered out to assure better 
cutting performance, and only the gRNAs with distance of cut site to targeted SNP not 
more than 10 nucleotides were selected for off-target effect analysis. The in silico 
predictions of their off-target effects were tested using COSMID73. The online tool is 
available through https://crispr.bme.gatech.edu/. 
2.2.3 Single cell clone generation 
HL60 (ATCC, Manassas, VA, USA, CCL-240) and HL60/S4 (ATCC, Manassas, 
VA, USA, CRL-3306) cells were grown in suspension at 2 × 105 to 1 × 106 cell/ml in 
RPMI-1640 with 10% FBS, 2 mM L-glutamine and 100 μg/ml normocin. After culturing 
for 18 hours to 24 hours, cells were pelleted at 200 g for 3 min. Used media was collected 
and filtered to obtain conditioned media. Bulk cells suspensions were serial diluted on a 
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96-well plate with conditioned media to facilitate cell growth. Statistically, there were 
wells that only had single cell. Alternatively, some single cell clones were generated by 
sorting bulk cells by flow cytometry on a BD FacsAria Fusion with 100-micron nozzle at 
37°C, and seeded onto each well of a 96-well plate with the same conditioned media.  
2.2.4 Myeloid lineage differentiation 
Differentiation of cells into neutrophils was achieved by culturing with 1 μM 
retinoic acid, RA 74. Cells were seeded 18 hours before treatment at 2 × 105 cell/ml. HL60 
cells were treated for 4 days and HL60/S4 were treated for 2 days. During differentiation, 
cell density and viability were checked every 24 hours to maintain 2 × 105 to 1 × 106 cell/ml 
cell density. Additional culture media with RA was added if needed. Cells treated with the 
same volume of ethanol were used as negative control.  
Differentiation of cells into monocytes was achieved by culturing with 100nM 
α1,25-dihydroxyvitamin D3(D3) dissolved in ethanol75. Cells were seeded at 1.5× 105 
cell/ml at least 18 hours before treatment. Both HL60 cells and HL60/S4 were treated for 
3 days. During differentiation, alive cell density was checked and normalized every 24 
hours to maintain 2.5 × 105/ml cell density. Additional culture media with D3 was added 
if required. Cells treated with the same volume of ethanol were used as negative controls. 
2.2.5 Flow cytometry 
After collection, cells were washed with PBS twice at room temperature. Cells 
under neutrophil differentiation were then incubated with 7-Aminoactinomycin D (7-
AAD) (ThermoFisher Scientific, Waltham, MA, USA, cat. no. A1310) and PE-conjugated 
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mouse anti-Human CD11b (clone ICRF44) (BD Biosciences, San Jose, CA, USA, cat. no. 
557321) or PE-conjugated isotype control mouse mAb (clone: MOPC-21) (Biolegend, San 
Diego, CA, USA, cat. no. 400112) for 40 min at 4°C in the dark. Samples were analyzed 
by BD FacsAria Fusion with 100 micron nozzle at 4°C. Cells under monocyte 
differentiation were incubated with V450 Mouse Anti-Human CD14 (BD Biosciences, San 
Jose, CA, USA, cat. no. 560349) and APC Mouse Anti-Human CD71 (BD, cat. no. 
551374), or V450 Mouse IgG2b (BD, cat. no. 560374) and APC Mouse IgG1 (BD 
Biosciences, San Jose, CA, USA, cat. no. 555751) for isotype control. Samples were 
analyzed by BD FACSMelody at 4°C. All data were analyzed with FlowJo software 
v10.6.1 downloaded from https://www.flowjo.com/. 
2.2.6 Immunofluorescence 
After collection, cells were washed with PBS twice at room temperature. Then, 
cells were incubated with Hoechst-33342 (ThermoFisher, Waltham, MA, USA, cat. no. 
H3570) for 10 to 15 min at 37°C in the dark. 10 µl of the cell suspension was used to make 
a slide, which was sealed with clear nail polish. UV excitation and microscopic imaging 
was done on an Olympus IX73 inverted microscope system. 
2.2.7 RNA isolation  
Cells were grown in suspension at 2 × 105 to 1 × 106 cell/ml in RPMI-1640 with 
10% FBS, 2 mM L-glutamine and 100 μg/ml normocin. Cells were seeded at 2 × 105 cell/ml 
18 hours to 24 hours before extraction. Each clone had two biological replicates, except 
bulk HL60/S4. One million cells from each sample were collected by centrifuging at 300 
g for 5 minutes. Total RNA was isolated and purified by RNeasy Plus Mini Kit (Qiagen, , 
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Hilden, Germany, cat. nos. 74134 and 74136). Quality control of RNA samples were 
assessed with a Bioanalyzer 2100 instrument (Agilent, Santa Clara CA).  
2.2.8 Bulk RNA-Seq and differential gene expression analysis 
cDNA library preparation for single cell clones was done using Illumina TruSeq 
Stranded Sample Preparation, Low Sample (LS) Protocol. Sequencing was performed on 
an Illumina HiSeq 2500 at Georgia Tech, generating 100 bp paired-end libraries with an 
average of 51.8 million paired reads per sample. Library preparation for differentiated cells 
was done using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New 
England BioLabs, Ipswich, MA, USA, cat. no. E7760S). Sequencing was performed on 
Illumina NextSeq, high output, generating 75 bp paired-end libraries with an average of 36 
million paired reads per sample. The gene expression data is available at the Gene 
Expression Omnibus (GEO) under the accession code GSE135507. 
RNA-Seq quality control was initiated with Trim Galore, which was used to trim 
the 13bp Illumina standard adapter (‘AGATCGGAAGAGC’) by default, after which 
quality control was reported by FastQC. Reads were mapped to hg38 human reference 
genome by STAR76, and on average the mapped reads were 90% of total reads. Aligned 
sequencing reads were counted with intersection-strict mode in HTSeq77 to get read counts 
for each gene. Scale factors of each sample were computed using the trimmed mean of M-
value (TMM) algorithm in the R package, edge R78. Raw read counts were normalized by 
scale factors and then transformed into log2 counts per million reads (CPM). Genes were 
kept if expressed in at least three samples. 11,746 genes were kept in single cell clone 
RNA-Seq, while 13,485 genes were kept in differentiated cell RNA-Seq. 
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Differential gene expression analysis was conducted in edgeR with generalized 
linear models to contrast effects of each treatment group. Pairwise comparisons between 
control and neutrophil derivative, control and monocyte derivative, as well as within each 
clone of each type of cell were performed. Likelihood ratio tests was assessed to obtain 
lists of differentially expressed genes and following Benjamini-Hochberg false discovery 
rate correction.  
Gene ontology analysis was performed using ToppFun79. By uploading a list of 
differentially expressed genes (FDR<0.001) from the differential gene expression analysis 
into the website, functional enrichment features were listed, including pathways, Gene 
Ontology (GO) terms and phenotypes. Gene ontology analysis was also performed by 
enrichR80,81 with four sets of differentially expressed genes (FDR<0.001) uniquely in HL60 
monocyte (968 genes), HL60/S4 monocytes (521 genes), HL60 neutrophils (1,462 genes) 
and HL60/S4 neutrophils (2,275 genes).  
Principal Component Analysis (PCA) was done performed on 17 single cell clone 
samples, and 47 differentiated cell samples by “prcomp” function in R, with default 
settings. Principal Variance Component Analysis (PVCA) was performed in JMP 
Genomics 8 (SAS Institute, Cary, NC, USA), which sums the weighted proportions of each 
variance component associated with covariates of interest in order to estimate the overall 
contribution of biological and technical factors to the gene expression variation. Plots were 
plotted with R package, ggplot2. 
2.2.9 Variant calling 
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Variants were called by GATK82,83 best practice RNA-seq short variant discovery 
(SNPs and Indels). Raw RNA-seq reads was mapped to hg19 by STAR76. 
“SplitNCigarReads” was used to split reads that span introns and hard clip mismatching 
overhangs. Variants were called by “HaplotypeCaller” with default settings. Due to the 
high false positive rate of calling variants from RNA-seq data, the “VariantFiltration” 
function was used to filter potential false positive calls. Clusters of at least three SNPs 
within a window of 35 bases were excluded and calls with read depth lower than 50 were 
filtered. Moreover, the variant calls were only included if they were consistent in the two 
biological replicates of the same clone, and only exonic polymorphisms were counted. 
2.2.10 Fluidigm qRT-PCR 
Fluidigm Real-Time qPCR was conducted on a 48 × 48 nanoscale microfluidic 
chip with 48 EvaGreen probes targeting transcripts of the CRISPR targeted genes, as well 
as a representative set of lymphoid and myeloid cell marker genes84, and housekeeping 
genes. The 48 array samples included single-cell clone CRISPR edited HL60/S4 from 
two batches and experimental controls. 2,304 qRT-PCR assays with 30 amplification 
cycles were conducted in parallel according to manufacturer’s protocol. Average Ct value 
was computed at the exponential phase of each PCR amplification reaction. Since large 
Ct values correspond, counter-intuitively, to low expression, modified expression values 
were computed as the Ct values subtracted from 30 (the maximum number of PCR 
cycles) and the negative outputs were set as 0. This results in a range from null to 30 
where each increment in theory represents a doubling of initial transcript abundance. To 
clean up the data, samples with more than 40 unexpressed genes and probes expressed in 
less than 5 samples were removed. Processed expression data and sample phenotypic 
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information are provided in online Tables S1 and S2 
(https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter2_supp_tables), 
respectively. We note that numerous studies have established the high sensitivity of 
Fluidigm relative to standard qRT-PCR85-87, and that all expression levels were in the 
normal range of detection and not subject to drop-out seen with very low abundance 
transcripts. 
2.2.11 Plasmid construction 
The SpyCas9 expressing plasmid pX330-U6-Chimeric_BB-CBh-hSpCas918 
(Addgene plasmid #42230) was a gift from Dr. Feng Zhang. The pX330 vector was 
digested by BbsI. For each designed gRNA sequence, a pair of annealed oligos was cloned 
into the vector before the gRNA scaffold and after the U6 promoter. All clones were 
validated by Sanger sequencing (Eurofins Genomics, Louisville, KY, USA). 
2.2.12 CRISPR-edited single cell clone generation 
A total of 2 × 105 HL60/S4 clone 3 cells and 1 μg of pX330 plasmid per 
nucleofection reaction (program CA-137, solution SF) were electroporated using the 
Lonza Nucleofector 4-D based on the manufacturer’s protocol. 1 μg of 
pmaxGFPTM Vector per nucleofection reaction was co-transfected as the reporter. The 
cells were cultured at 37°C for 72 hours after nucleofection, and the GFP positive cells 
were sorted individually by BD FACSMelody to make single-cell clones following 
standard protocols. Post-sorting, cells were grown for a week before harvesting and DNA 
extraction. DNA was extracted using Quick-DNA Miniprep Plus Kit (Zymo Research, , 
Irvine, CA, USA, cat. no. D3024) following the manufacturer’s protocol. For each target 
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locus, a PCR product was amplified from the genomic DNA of cells modified by 
CRISPR/Cas9 and analyzed by Sanger Sequencing (Eurofins Genomics, Louisville, KY, 
USA). The genotypes of clones selected in this study are shown in online Table S3a 
(https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter2_supp_tables), and the 
number of clones screened, and mutations observed per clone are shown in online Table 
S3b (https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter2_supp_tables). 
2.2.13 Power simulation studies 
Power analysis was performed using the Mixed Model Power expression utility in 
JMP Genomics (SAS Institute, Cary, NC, USA). We created a design file with duplicates 
of 10 gRNAs, and designated one guide as the causal variant. Additional random effect 
options for representing Batch effects (distributing the guides across into two batches of 
5), and Clone effects (where the causal variant was represented by two different clones) 
allowed modeling of the impact of these additional sources of variance. We assessed power 
at alpha = 0.05, 0.01, and 0.001 for effect sizes of the causal variant in increments of 0.1 
standard deviation units (sdu) between 0 and 2, assuming experiments with 2, 4, 8 or 16 
replicates of each guide. Batch and Clone effects were assumed to be 0.1 or 0.2 sdu. For 
an additional analysis, three of the guides were assumed to affect gene expression, 
modeling the situation where multiple linked variants account for an eQTL effect. 
2.3 Results 
2.3.1 Effect of Clonal Variability on Gene Expression in HL60 Cells 
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Since genetic screens are best performed in uniform genetic backgrounds under 
conditions where environmental variation can be carefully controlled, we started by 
evaluating the magnitude of effect of biological and technical factors on gene expression 
in HL60 cells. HL60 is a pro-myeloid cell line derived from a person with acute 
promyelocytic leukemia88,89. It is known to be homozygous for a TP53 deletion and a 
CDKN2A premature stop codon, and heterozygous for an NRAS missense substitution. The 
main factors of interest were (i) batch effects, (ii) HL60 sub-type, (iii) clonal heterogeneity, 
and (iv) differentiation status. A derivative known as HL60/S4 has been isolated which is 
reported to more efficiently differentiate into myeloid derivatives such as neutrophils and 
macrophages90. Given the almost 40 years in culture, we reasoned that point mutations that 
are likely to affect overall gene expression may have accumulated, and to control for this 
isolated 3 single cell clones (labelled 1 through 3) of HL60, and 4 single cell clones 
(labelled a through d) of HL60/S4. Differences in growth rates among clones and relative 




Figure 2.1 Heterogeneity of gene expression in single cell clones and myeloid lineage 
differentiated clones. (a) Principal component analysis (PCA) of bulk RNA sequencing 
of parental single cell clones and bulk cells. PCA was performed on normalized log2 
CPM count expression matrix of 17 samples from HL60 and HL60/S4 generated single 
cell clones. Each dot represents 17 samples, two biological replicates for each clone and 
bulk, except for HL60/S4 bulk. Samples are colored by clones: warms color dots are 
samples from HL60/S4 cell lines, while cold color dots are samples from HL60 cell lines. 
PC1 separates samples by cell type, explaining 57.6% of the total variation. PC2 separate 
samples by clones, representing 9.8% of the total variation. (b) Principal variance 
component analysis shows the weighted average proportion of each variance component, 
cell type (85.4%), clone (14.3%) and residual (0.3%), all of which explain variance 
captured by the first five principal components (86.8% of total variance). Majority of the 
total expression variance of single cell clones is explained by cell type and clone variance 
components. (c) Principal component analysis of bulk RNA sequencing of myeloid 
lineage differentiated clones, performed by normalized log2 counts per million (CPM) 
expression matrix. Each dot represents 47 samples from differentiated monocytes and 
neutrophils and undifferentiated control cells, two biological replicates for each 
stimulation on each clone. Clone d is excluded due to sequencing error. Samples are 
colored by cell type and differentiation lineages: monocytes are green, neutrophils are 
blue and control cells are red. To distinguish the original cell type of each sample, HL60 
cells are dark colors and HL60/S4 cells are light colors. (d) Principal variance component 
analysis shows the weighted average proportion of each variance component, original cell 
type (38.5%), differentiated type (36.8%), clone (8.1%) and residual (16.6%), all of 
which explain variance captured by the first five principal components (83.9% of total 
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variance). The 16.6% of unexplained variance may from the variance of biological 
replicates and culture differences between two labs. 
Clonal variability in gene expression was monitored by bulk RNA-seq of two 
batches for each of the 7 single cell clones and 2 parental lines. Figure 2.1a plots the first 
two principal components (PC) of expression of 11,746 expressed genes detected with an 
average depth of over 50 million paired-end 100 bp reads per sample. PC1 separates the 
two HL60 sub-types unambiguously, and 85% of the variance attributable to the first 5 PC 
(86.8% of total variance) is between HL60 and HL60/S4 cells. Individual clones separate 
along PC2 with relatively little separation between replicates, with the parental lines taking 
intermediate values. Just 14% of the variance is among clones, but residual replicate effects 
account for less than 1% of it (Figure 2.1b). These results confirm that single cell clones 
are likely genetically differentiated, implying that as far as possible CRISPR/Cas9 editing 
should be performed on a purified clone. 
The extent of genetic differentiation of single cell clones was evaluated by calling 
genotypes directly from the RNA-seq data. Given that false positive calls are elevated due 
to errors induced by the reverse transcriptase during cDNA preparation, and that allele-
specific expression causes SNP ratios not observed in genomic DNA sequence data, we 
applied variant hard filtering in GATK. Clusters of at least three SNPs within a window of 
35 bases were excluded, the variant calls were only included if they were consistent in the 
two biological replicates of the same clone, and only exonic polymorphisms were counted. 
On average, each of the HL60 single cell clones differed from the bulk consensus sequence 
at 103 of the 7482 single nucleotide variants (1.38%) passing our hard filters. A little over 
fifty percent more divergence, 166 of 7104 SNVs (2.34%) were uniquely observed in 
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HL60/S4 pairwise clonal comparisons with the bulk HL60/S4 consensus. Furthermore, 
approximately 3% of the total SNVs were different in the comparison of bulk HL60/S4 
and HL60 lines and their derivatives, indicating that there is considerable genetic 
variability both between the two lines and in single cell clones. Similar findings were 
reported91 in an analysis of somatic mutation accumulation in a cancer cell line.  
Next, we asked how consistent chemical-induced differentiation is across clones. 
Each of the single cell clones, with the exception of HL60/S4 clone d, was treated with 1 
μM retinoic acid for 4 days (HL60) or 2 days (HL60/S4) in order to generate neutrophil-
like cells, or with 100nM α1,25-dihydroxyvitamin D3 for 3 days in order to generate 
monocyte-like cells. Figure 2.2 shows characteristics of the cells stained with Hoechst to 
monitor changes in morphology of the nucleus, 7-AAD to monitor cell viability, and 
CD11b, a neutrophil marker. Growth conditions were chosen to optimize the balance of 
cell differentiation and viability, which also varied among clones. As previously 
reported90, HL60/S4 cells more readily differentiated toward neutrophil fate than did 
HL60 cells. Figure 2.3 confirms initiation of CD14 expression, as well as loss of CD71, 
both markers of monocyte fate, to similar degrees in both bulk HL60 and HL60/S4, 
though variation among clones of HL60 was also seen (online Table S4a,b, 
https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter2_supp_tables), including 
variability of cell surface marker expression at baseline. 
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Figure 2.2 Characteristics of neutrophils by immunofluorescence and flow 
cytometry analysis. Left two panels show the Hoechst staining of multilobular nuclei of 
differentiated neutrophils. A representative figure of one clone of each cell type, HL60 
and HL60/S4. The cell pointed by the arrow represents two lobes of the nucleus. The 
right panel shows flow cytometry analysis of CD11b (cell surface marker for neutrophil) 
expression and 7-AAD staining to stain dead cells. The gated populations with cell 
proportion show CD11b-/7-AAD+, live undifferentiated cells (bottom left quadrant) and 





Figure 2.3 Characteristics of monocytes by flow cytometry analysis. The flow 
cytometry analysis of CD71 and CD14 expression in control and monocyte differentiated 
HL60 bulk, HL60 clone b and HL60/S4 bulk cells. The gated population (Q1) with cell 
proportion shows monocytes (CD71-/CD14+). 
As with the untreated clones, gene expression was again observed to vary 
substantially between the two sub-types and among clones, with a generally uniform 
response to treatment and relatively small differences between replicates (Figure 2.1c). In 
a joint analysis, HL60/S4 cells tend to have more positive values of PC1 and negative 
values of PC2 than HL60, and the overall cell-type accounts for 38.5% of the variance 
captured by the first five PC (83.9% of total variance). Neutrophils occupy an intermediate 
position between monocytes and undifferentiated cells along both PC axes, and cell fate 
captures 36.8% of the variance. At baseline, HL60/S4 cells appear to be more divergent 
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from the derived neutrophil-like and, especially, monocyte-like cells than are HL60 from 
their derivatives. Clonal differences remain significantly higher than replicate effects.  
In total, 5,885 and 3,319 genes (FDR<0.0001) were identified that were 
differentially expressed before and after monocyte and neutrophil lineage differentiation 
across all clones of two cell types, HL60 and HL60/S4, respectively.  
After differentiation, HL60/S4-derived monocyte cells were more transcriptionally 
divergent from their parental cells than were HL60-derived monocytes: 7,381 monocytic 
differentially expressed genes were detected in HL60/S4, compared with 4,167 genes in 
HL60. B2M, a neutrophil-specific differentiation marker, is one of the 4,167 genes that 
were differentially expressed in the neutrophil-derived clone a, clone b, and HL60 bulk 
cells. There were 5,079 differentially expressed genes in the monocyte derivatives of 
HL60, including the transcription factors CEBPE specifically in clone c derivatives, and 
PU.1 in clone b derivatives. Similar gene markers were also documented in a time course 
of myeloid differentiation92, although we observed a higher number of differentially 
expressed genes at the terminal differentiated stage of monocytes than neutrophils, whereas 
the opposite pattern was found at 6 hour post-differentiation92.  
Differences in the degree of inter-clonal differentiation were also detected (Figure 
2.4). For the monocyte derivatives, 1,781 genes were differentially expressed relative to 
undifferentiated cells in all of the clones of the two cell types, and these were enriched in 
cell cycle, neutrophil degranulation, and rRNA processing pathways. On the other hand, 
968 genes were uniquely differentially expressed in the HL60 clonal comparisons, also 
showing enrichment for neutrophil degranulation and innate immune system pathways. 
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Gene ontology (GO) and pathway analysis was performed by Toppfun, and the significant 
GO terms and pathways (Bonferroni corrected p-value < 0.00001) for these 968 genes were 
listed in Figure 2.5. Similarly, for neutrophil lineage differentiation, 413 differentially 
expressed genes were shared by HL60 and HL60/S4, enriched for neutrophil degranulation, 
innate immune system activity, interleukin-10 signaling, chemokine signaling and cytokine 
signaling pathways. There were 1,462 and 2,275 clonal specific differentially expressed 
genes in HL60 clones and HL60/S4 clones, respectively, engaging pathways involved in 
cell cycle and mitochondrial function, translation and rRNA processing were also enriched. 
Significant GO terms and pathways (Bonferroni corrected p-value < 0.00001) for HL60 
and HL60/S4 were shown in Figure 2.6 and 2.7, respectively. Gene ontology enrichment 
analysis of uniquely differentially expressed genes was also performed using the gene set 
enrichment tool Enrichr80,81, with results summarized in Figure 2.8.  
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Figure 2.4 Venn diagram of differential expressed genes. The Venn diagrams show 
the number of significant inter-clonal differentially expressed genes (FDR<0.0001) in 
monocyte lineage (a) and neutrophil lineage (b) differentiation in HL60 and HL60/S4.   
 
Figure 2.5 Gene ontology and pathway analysis of differential expression genes in 
HL60 monocyte derivatives. Uniquely differentially expressed genes in HL60 
monocytes (968) were used as input to perform gene ontology and pathway analysis by 
Toppfun. Gene ontology terms involving in biological process and molecular function, 
and pathways are categorized and listed on the vertical x-axis. And the number of DE 
genes involved in each term is shown on the horizontal y-axis.  P-value is corrected by 




Figure 2.6 Gene ontology and pathway analysis of differential expression genes in 
HL60 neutrophil derivatives. Uniquely differentially expressed genes in HL60 
neutrophil (1,462) were used as input to perform gene ontology and pathway analysis by 
Toppfun. Gene ontology terms involving in biological process and molecular function, 
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and pathways are categorized and listed on the vertical x-axis. And the number of DE 
genes involved in each term is shown on the horizontal y-axis.  P-value is corrected by 
Bonferroni correction with 0.00001 as cut-off. 
 
Figure 2.7 Gene ontology and pathway analysis of differential expression genes in 
HL60/S neutrophil derivatives. Uniquely differentially expressed genes in HL60/S4 
neutrophil (2,275) were used as input to perform gene ontology and pathway analysis by 
Toppfun. Gene ontology terms involving in biological process and molecular function, 
and pathways are categorized and listed on the vertical x-axis. And the number of DE 
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genes involved in each term is shown on the horizontal y-axis.  P-value is corrected by 
Bonferroni correction with 0.00001 as cut-off. 
 
Figure 2.8 Gene ontology enrichment analysis of differential expression genes in 
HL60 and HL60/S4 monocyte and neutrophil derivatives. Uniquely differentially 
expressed genes in HL60 monocytes (968), HL60/S4 monocytes (521), HL60 neutrophils 
(1,462), HL60/S4 neutrophils (2,275) were used as input to perform gene ontology 
enrichment analysis by Enrichr. The total number of genes in each cell type term is 
shown on the y-axis and the number of DE genes enriched in each term is shown next to 
each dot. p-value and combined score (log(p-value) × z-score) are coded by the color and 
size of dots, respectively. 
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Taken together these results imply that single cell clones differ in basal gene 
expression, and although they respond similarly to treatment with retinoic acid or vitamin 
D3, clonal differences need to be accounted for when evaluating the effect of 
CRISPR/Cas9 mutagenesis of regulatory regions of target genes. 
2.3.2 Isolation and evaluation of CRISPR/edited single cell clones  
We selected 7 SNPs in 4 genes for our initial evaluation of the effect of non-
homologous end-joining (NHEJ)-based CRISPR mutagenesis in HL60/S4 clone 3 as a 
uniform genetic background. SDCCAG3, NFXL1, and AMFR were each targeted for a 
single peak eQTL SNP detected by whole blood gene expression, whereas CISD1 was 
targeted with 4 SNPs in one credible eQTL interval. Potential off-target sites analysis of 
each gRNA with up to two mismatches are provided in online Table S5 
(https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter2_supp_tables). With 
genome wide bioinformatic screening, none of potential off-target sites were located in 
coding regions and the gRNAs have no extra perfect match other than the designed target 
site. Bulk transfection efficiency was 24.8% based on percentage of cells expressing GFP 
signal. GFP positive cells were considered capable to uptake plasmid vectors and were 
single cell sorted to enrich the edited cells. Of all expanded GFP positive single cell clones, 
23 out of 166 had obtained Indels, 8 of which had removed the target SNP at both allelic 
copies, while the remainder affected sequences immediately adjacent to the target SNP or 
only had SNP removal in one allele.  
RNA-seq would be prohibitively expensive for comparing gene expression on the 
scale of dozens of multiply replicated clones, so we next evaluated the potential of high 
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throughput nanoscale quantitative RT-PCR to detect subtle differences in transcript 
abundance. A 48×48 Fluidigm chip was designed, facilitating measurement of 48 genes 
(including the four targets, housekeeping controls, and various markers of expression in 
diverse immune cell type) in 48 samples. The HL60/S4 parental cell line and eight clones 
were chosen for profiling, one for each guide RNA, and each was grown in duplicate in 
suspension for 18-24hrs, with half the sample frozen down for storage, and the other half 




Figure 2.9 Quantification of gene expression by Fluidigm qRT-PCR and analysis of 
the variance components. Kernel density plot of standardized gene expression from 
each sample, color coded by batches, before (a) and after (c) removing batch effect. 
Before (b) and after (d) batch effect correction, principal variance component analysis 
showed the weighted average proportion of each variance component: batch 65.3%, 0%, 
respectively; target gene 5.6%, 9.2%, respectively; gRNA 3.2%, 9.2%, respectively; and 
residual 25.8%, 81.6%, respectively. All of the components explained variance captured 
by the first five principal components (99.1% and 99.1% of total variance, respectively). 
(e) Expression of CISD1. Pairwise t-test has done to test the difference between 
CRISPR/Cas9 edited samples (RG16, RG17, RG19 and RG20) and negative control. 
RG16, RG19 and RG20 were significantly different from the negative control. * denotes 
p-value<0.05; ns, not significant. 
For ease of interpretation, we subtracted the Ct value for each measurement from 
the number of PCR cycles, 30, resulting in expression values where high values correspond 
to high expression. Figure 2.9a shows that this results in a bimodal distribution of gene 
expression measures, with the smaller peak representing low-abundance transcripts. There 
was a major difference in the profiles of the frozen and fresh cells, accounting for almost 
two thirds of the variance explained by the first five PCs (99.1%) (Figure 2.9b). To correct 
for this batch effect, we used Combat, which also standardizes the data to a mean of zero 
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and standard deviation of one (Figure 2.9c). On this scale, most of the variance is now 
among samples, whereas 9% of first five PCs (99.1%) distinguishes clones by which gene 
was targeted, and 9% is due to differences among gRNAs for CISD1 (Figure 2.9d). This 
implies either that single gene knockouts affect the expression of a substantial number of 
other genes in each clone, or that there is substantial variability among clones that by 
chance correlates with the nature of the guide RNA. We also observed that normalized 
CISD1 expression was lower in cells edited by each of the four gRNAs targeting CISD1 
than in the untreated control parental cell line (Figure 2.9e). Clone RG17 affected a control 
SNP in high LD with the peak eQTL but with low CADD score69,93 and high evolutionary 
probability70 of the alternate allele, and was the only clone not significantly different from 
the parental line. However, since it is unlikely that each of the other three sites causally 
influence gene expression, this result serves as a further caution that the process of 
transfection with CRISPR reagents itself may influence cell growth and gene activity. 
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Figure 2.10 Quantification of all targeted gene expression in all CRISPR/Cas9 
edited single cell clones by Fluidigm qRT-PCR (Table S4, S5). HPRT and GAPDH are 
housekeeping controls. Single cell clones were grouped by guide RNA and the expression 
of seven probes was shown as boxplot across all clones within each guide RNA group. 
Clones with the same genotype in each guide RNA group were colored coded. Pairwise t-
test has done to test the difference between CRISPR/Cas9 edited clones and HL60/S4 
negative control. * denotes p-value<0.05; ns, not significant. 
Similarly, inconsistent results were obtained for the other three genes, as 
summarized in Figure 2.10. Each panel shows box-and-whisker plots for each of the 7 
guide RNAs and control HL60/S4 cells, with the mean and interquartile range of 9 single 
cell clones measured with two different PCR probes for three of the genes and one for 
SDCCAG3. In no case is the expression the most extreme for the guide RNA corresponding 
to the linked gene. For example, AMFR expression was highest in cells carrying a mutation 
in the RG16 guide disrupting a candidate regulatory site in CISD1, whereas AMFR 
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expression itself was on average the closest to expression in the control cells. Disregarding 
the control, there were also no cases where the appropriate guide RNA was significantly 
different from the remaining guides. These results imply either that the selected SNPs are 
not causal, or that the effect sizes of causal variants are too small relative to the observed 
experimental variability to detect differential expression. 
2.3.3 Simulation studies to establish power of Fluidigm-based single cell regulatory 
assessment 
We used these results to guide our design and interpretation of power calculations 
for experiments designed to determine the effect of single regulatory site disruption. Our 
baseline scenario assumes targeting of 10 polymorphisms in a single credible interval in 
which a single eQTL is assumed to account for at least 10% of the variance in transcript 
abundance at the locus. Such an eQTL corresponds to a difference of approximately 1 
standard deviation unit (sdu) in a quantitative assay such as Fluidigm qRT-PCR or RNA-
seq. Given that most single cell CRISPR/edited clones are heterozygous, it also 
corresponds to a substitution effect whereby the mutant allele increases or decreases the 
measured transcript by 1 sdu. We used the Mixed Model Power calculator in JMP-
Genomics (Cary, NC, USA) to evaluate the sample size needed to detect an effect of this 
magnitude given varying levels of clonal variation, batch effects, and mutation differences.  
For the baseline scenario where there are neither batch nor clonal effects, 80% 
power to demonstrate that one SNP has an effect that is at least 1 sdu different from the 
other nine SNPs is achieved with 8 replicates of each of the ten clones (Figures 2.11a, f). 
16 replicates would enable detection of an effect as small as 0.7 sdu, but 4 replicates would 
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only be powered to detect a substitution effect of 1.5 sdu. However, the experimental data 
indicates that individual clones generally do vary, as a consequence of genetic background 
effects if the transfected cell line was not isogenic, or growth differences among aliquots. 
Modelling these differences as a random effect of just 0.2 sdu among the ten clones 
demonstrates a dramatic reduction in power to detect the main effect (Figures 2.11b, g). 
With 8 replicates, only an effect size of 1.7 sdu is reliably detected, though 40% power is 
still obtained for an effect size of 1 sdu. Doubling the size of the experiment only slightly 
improves the power, whereas 4 replicates only facilitates detection of effect sizes of 2 sdu. 
If we further consider the scenario with a batch effect whereby half the clones have an 
additional random effect of 0.2 sdu (perhaps because they were grown at a different time), 
then power reduces yet again, as expected (Figures 2.11c, h). 
A perhaps more realistic scenario is where different edits of the same polymorphic 
site also have different impacts on gene expression. This could either be because the precise 
nature of the deletion matters, or because the independent clones have slightly different 
growth properties. We modelled this scenario by allowing for two different clones 
representing the causal variant, also with a 0.2 sdu random effect difference, the same as 
the effect of the other 9 guide RNAs. In this case (Figures 2.11d, i), 80% power is never 
achieved, so it would take greater levels of replication at least of the putative causal variant 
to see a substitution effect in the range of 1 sdu. 
A related situation is where more than one of the polymorphisms in the credible 
interval is responsible for the eQTL effect – for example, three sites in high LD might each 
account for 0.33 sdu, summing to a combined effect of 1 sdu. To model this, we set 3 of 
the guide RNAs to be causal, with the other 7 non-functional, but retained 0.2 sdu 
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differences among clones. Figures 2.11e, j show that power is greater than the same 
scenario with one causal variant, and approximately the same as with one causal variant 
and no differences among the remaining clones. Power is actually greater with fewer 
replicates (red and blue curves), but with 8 replicates 80% power still only detects an effect 
size of 1 sdu, which is three times larger than the presumed individual effect sizes of the 
contributing causal variants. 
 
Figure 2.11 Power curves of Fluidigm-based single cell clone regulatory assessment 
of simulation studies. (a)-(e) diagrams five different scenarios, and the corresponding 
panels (f)-(j) show the power calculations for exceeding a nominal p-value of 0.05, with 
blue, red, green and brown curves representing 2, 4, 8 and 16 technical replicates of each 
clone respectively. The y-axis is the power from 0 to 100 percent, and the x-axis is the 
effect size of eQTL in standard deviation unit. 
2.4 Discussion 
Multiple studies have recently reported good success in mapping regulatory intervals 
using high throughput approaches in human cells. A previous study37 scanned across over 
100 kb of regulatory DNA in the TP53 and ESR1 genes using positive selection for 
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proliferation to enrich cells with aberrantly low expression of the target transcription 
factors, defining several intervals enriched for signals that overlap with transcription factor 
binding sites. This approach is however dependent on the ability to select on locus, and 
similar to methods that sort on the basis of an engineered selectable fluorescence protein94, 
only identifies high-impact sites without necessarily discriminating effects of polymorphic 
sites. Another approach95 used CRISPRa to map enhancer elements by virtue of activation 
of regulatory protein-DNA interactions, filtering a handful of short DNA stretches from 
hundreds of kb of intergenic sequence in the IL-2RA gene, but again without the ability to 
resolve which of the SNPs in a credible interval are responsible for an eQTL. Expression 
CROP-seq is powered to fine-map eSNPs with 10%-20% effect size within credible 
intervals by characterizing hundreds of CRISPR/Cas9 genetically mutated single-cell 
transcriptomes in parallel96. Tewhey et al,31 first demonstrated the utility of massively 
parallel reporter assays, including the ability to discriminate between alleles at a site. Their 
results and findings from others97,98 imply that at least 5% of all polymorphisms in 
regulatory DNA have the potential to regulate target gene expression. The concern remains 
though that such effects may be artefacts of short reporter genes assayed outside the context 
of chromatin and complex regulatory interactions. 
Our approach instead borrows from classical quantitative genetic screens in model 
organisms such as drosophila and yeast. The objective is to create a panel of genetic 
perturbations in an isogenic background, evaluating the quantitative impact of each variant 
relative to the frequency distribution of effects of all other perturbations. For example, P-
element insertion screens cleanly identified dozens of genes influencing aging, bristle 
number and aspects of fly behaviour99,100. Closer to our experiments, another study101 
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engineered a tiling path across the regulatory region of the TDH3 gene in Saccharomyces 
cerevisiae and used flow cytometry to quantify gene expression of hundreds of strains, 
drawing inferences about the impact of stabilizing selection on transcription. We reasoned 
that a similar approach should be powerful for moderate-sized laboratories without 
extensive experience in human cell culture. Even though we, and others, have successfully 
documented regulatory effects of CRISPR/Cas9 mutagenized candidate mutations of large 
effect55,102, the results here applied to typical moderate-effect size eQTL do not support 
this as a general protocol. The remainder of the discussion deals with multiple constraints 
on the effectiveness of single cell clone-based screening to dissect credible regulatory 
intervals in human cell lines. 
The first constraint is variability in mutability of targeted regulatory sites. Our 
approach was mainly limited in three ways: the requirement of nearby PAM sequences 
and the short distance between the cut site and targeted SNP, the variable efficiency of 
different gRNAs, and the distinct Indel pattern for each SNP targeted gRNA. We started 
with a list of 250 candidate polymorphisms, approximately 10 each in two independent 
eQTL intervals of 13 genes, but discovered that only two-thirds of these were suitable 
CRISPR targets, either because there was no nearby PAM sequence or the target was in 
repetitive DNA for which it was not possible to design a guide RNA with a unique target 
sequence. Up to 20% of the remaining sites were predicted to have high probability off-
target sites elsewhere in the genome, which may not matter for a scan of cis-acting effects 
but is not ideal. Subsequently, we chose 10 sites as a pilot, and screened an average of 24 
single cell clones for each site (23.9 ± 6.7) by Sanger sequencing of the targeted region. 
As shown in online Table S1B 
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(https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables), the pilot 
group had an average of 4 clones each with Indels on both alleles (3.8 ± 1.8).  The ratio 
of clones with Indels on both alleles varied from 0% (RG11) to 25% (RG16) so that the 
theoretical maximum SNP removal rate were different in each gRNA treated group.  
RG14, 17, 19, 20 and 34 all had designed cut <5bp to the targeted SNP, but their 
percentage of SNP removal on both alleles varied from 0% to 16%, which could be due 
to variations in the size of Indel mutations as previously observed103. That is to say, many 
of the CRISPR-induced mutations removed or inserted one or a few nucleotides either 
side of the polymorphic site without disrupting the polymorphism itself. We conclude 
that obtaining at least 4 different clones for a minimum of 20 sites associated with a 
credible eQTL interval would typically require screening of 500 clones following various 
iterations of guide RNA design, with less than 100% success and at considerable 
expense. Allelic replacement by CRISPR-mediated homologous repair would be even 
more difficult. There are more potential optimizations that may help researchers deal with 
this constraint. Further optimization can be done in transfection, such as the co-
transfection ratio of two plasmids. It is possible that different cell lines would have higher 
efficiency of mutagenesis. Other CRISPR/Cas9 delivery methods, such as lentivirus 
transduction, can also be beneficial for a more efficient screening. 
The second constraint is clonal variability. We started by addressing a major concern 
with human cell lines, which is mutational accumulation in culture. Previous studies91 
showed that tumor cell lines diverge genetically in as few as a dozen passages, resulting in 
divergent drug responses and gene expression profiles. Accordingly, single cell cultures of 
HL60 and the derivative HL60/S4 cell lines are different at the DNA sequence level, and 
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have significantly different transcriptomes, both with and without chemical stimulation of 
differentiation. For a considerable proportion of genes, these differences are of a similar 
order of magnitude as expected eQTL effects, namely 20% to 50% differences in 
normalized abundance. While this observation strongly supports the decision to 
mutagenize a single cell clone, genetic differences may not actually be the major source of 
clonal variation. Mammalian, including human, cells are much more difficult to culture 
than yeast or bacteria, as thawed aliquots of frozen lines are well known to differ in growth 
rates and viability. The technical replicates in Figure 2.1 were all grown in parallel, so do 
not capture this type of batch effect, which we have not sought to quantify. However, we 
note that parallel culture of the nine mutant clones analysed was made difficult by variable 
growth rates, and that some thaws failed to grow at all, requiring expansion of new aliquots. 
Consequently, batch effects of single cell clones are a hidden but likely considerable source 
of gene expression variability. 
A third constraint is expense. Assuming that the cost of RNA sequencing including 
cell culture, RNA preparation, library construction, and quality control could be reduced 
to $100 a sample using for example 3’ tagging, an experiment with 8 replicates of 20 clones 
would still cost $16,000. Instead, we adopted a nanoscale quantitative RT-PCR approach, 
the 48×48 Fluidigm array. Each of the data points in Figure 2.10 is actually the average of 
4 technical replicate qRT-PCR reactions on one plate at a cost of just $1.20 per assay (not 
including culture and RNA preparation). Technical repeatability is very high with repeated 
measures typically within 10%, also allowing measurement of dozens of genes 
simultaneously, so Fluidigm, or similar methods like Nanostring, provides a feasible 
approach in theory. 
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However, the fourth constraint, statistical power, emerged as the most serious 
impediment. A typical eQTL explains between 10% and 20% of the variance in expression 
of the gene it influences, which corresponds approximately to each allele increasing or 
decreasing transcript abundance between 0.5 and 1 standard deviation units. We modelled 
the power to detect such an effect in 80% of experiments given the variance components 
observed in our experiments and found that in the best-case scenario, 8 biological replicates 
would be needed to reliably detect a 1 sdu effect. However, addition of modest batch 
effects, subtle guide RNA differences within a locus, and small differences between 
different mutations induced by the same clone, power drops considerably. All such effects 
are apparent in Figure 2.10, suggesting that the single clone analyses, while demonstrably 
capable of discriminating very large regulatory effects of 2 or more sdu, are not generally 
likely to be detected with this approach. Cell lines other than HL60 may provide more 
repeatable results than we observed, which may improve power under some circumstances. 
It is possible that cell lines other than HL60 may provide more repeatable results than those 
described here, which may improve power under some circumstances. In this sense, 
independent valuation of the magnitude of batch effects for different cell lines under 
different growth conditions may be advisable, though we doubt that it will make single cell 
mutagenesis an optimal screening approach. 
Finally, a fifth constraint is the assumption that each eQTL can be reduced to a single 
eSNP. This is the parsimonious assumption and fits readily with the conception that 
regulatory SNPs exert their effects by altering the binding affinity for a specific 
transcription factor. Even though most eQTL span 100 or more polymorphisms in a 
credible interval, the general assumption is that prioritizing variants according to functional 
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criteria and evolutionary conservation, using scores such as CADD or LINSIGHT, reduces 
the search space to fewer than ten candidates. However, given that these variants are in 
tight linkage disequilibrium with similar frequencies61, if they have similar functional 
scores, then it is possible that the observed univariate eQTL effect is actually due to the 
summation of two or more smaller contributing effects. Under this scenario power to detect 
multiple causal variants is also reduced. 
These considerations and the overwhelmingly negative results of our experiments 
lead us to the recommendation not to pursue single clone-based profiling as a general 
approach to fine mapping of regulatory variants. Despite the conceptual limitation that 
effects are evaluated outside the context of normal chromatin, massively parallel reporter 
assays seem to be more powerful and subject to less experimental constraint.  
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CHAPTER 3. FINE-MAPPING WITHIN EQTL CREDIBLE 
INTERVALS BY EXPRESSION CROP-SEQ  
ABSTRACT: The majority of genome-wide association study (GWAS)-identified SNPs 
are located in noncoding regions of genes, and are likely to influence disease risk and 
phenotypes by affecting gene expression. Since credible intervals responsible for genome-
wide associations typically consist of 100 or more variants with similar statistical support, 
experimental methods are needed to fine map causal variants.  We report here a moderate-
throughput approach to identifying regulatory GWAS variants, expression CROP-seq, 
which consists of multiplex CRISPR/Cas9 genome editing combined with single cell 
RNAseq to measure perturbation in transcript abundance. Mutations were induced in the 
HL60/S4 myeloid cell line nearby 57 SNPs in three genes, two of which, rs2251039 and 
rs35675666, significantly altered CISD1 and PARK7 expression, respectively, with strong 
replication and validation in single cell clones.  The sites overlap with chromatin 
accessibility peaks, and define causal variants for inflammatory bowel disease at the two 
loci.  This relatively inexpensive approach should be scalable for broad surveys and is also 
implementable for the fine mapping of individual genes. The above is published in Biology 
Methods and Protocols. This work was performed in collaboration with the group of Dr. 
Gang Bao, supervised by Dr. Ciaran Lee and with wet lab experiments performed by Dr. 
Yidan Pan at Rice University. My contribution was mostly the statistical analysis and 
writing of the paper. Single-cell RNA sequencing was performed in Georgia Tech by Dr. 
Dalia A. Gulick. 
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3.1 Introduction  
The majority of genome-wide association study (GWAS)-identified SNPs are 
located in non-coding regions of genes, and are likely to influence disease risk and 
phenotypes by affecting gene expression104. Fine mapping of causal variants responsible 
for these signals is important for understanding which genes mediate phenotypic variation, 
dissecting mechanisms of action, assembling regulatory networks, and designing 
therapeutic interventions.  It is recognized increasingly that GWAS peaks have a complex 
structure, the resolution of which is limited by linkage disequilibrium (LD) and the 
presence of multiple independent signals at many loci55,56,105. Since GWAS peaks often 
overlap with expression QTL (eQTL) signals, namely associations with gene expression, 
transcription-based experimental screening approaches can be used to prioritize likely 
causal variants within credible intervals that contain 100 or more polymorphisms. Two 
classes of approach have been reported, CRISPR/Cas9 genome editing38, and massively 
parallel reporter assays (MPRA)33, but have not been developed to systematically scan 
across the regulatory element(s) of a target gene.   
Previous high-throughput CRISPR-based approaches to dissecting the impact of 
noncoding DNA have focused on defining cis-acting regulatory elements, rather than 
allelic effects of polymorphisms. They have generally utilized selection strategies followed 
by sequencing of barcodes from bulk cellular populations, assaying for enrichment or 
depletion of guide RNAs (gRNAs) targeting elements that are required for gene expression. 
In this way, Sanjana et, al106 surveyed 700kb around the NF1, NF2, and CUL3 loci by 
selecting for resistance to inhibition of BRAF in a melanoma cell line when transcription 
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of the genes is reduced, and Rajagopal et, al35 tiled 40kb around four genes into which they 
had inserted a green fluorescence protein marker to select for gene expression.   
Extending this approach genome-wide, two groups have surveyed function of the 
majority of binding sites for p53 and Estrogen Receptor-α in the context of oncogene-
induced senescence in a breast cancer cell line37, and for FOXA1 and CTCF mediation of 
target gene activity in breast and prostate cancer cell growth36. These experiments define 
enhancer elements required for essential gene function, and incidental findings related to 
the existence of polymorphisms in some elements are reported, but they do not provide a 
mechanism to systematically scan candidate SNPs in credible intervals.  
Here we report an adaptation of the CROP-seq protocol42, for regulatory fine-
mapping. CROP-seq (CRISPR droplet sequencing) involves multiplex CRISPR/Cas9 
transfection of a cell line with dozens to hundreds of gRNAs targeting different genes, 
followed by single cell RNAseq (scRNAseq) transcriptome profiling to monitor the 
consequences of inferred editing of the target gene.  Even though not all cells are edited, 
the ability to detect which gRNA was present in each sequenced cell allows quantitative 
comparison of the effect of loss of function of the gene.  In expression CROP-seq, we 
instead transfect dozens of gRNAs targeting different eSNPs in a credible regulatory 
interval and use the scRNAseq to monitor abnormal expression of linked transcripts 
(Figure 3.1).  Microdeletion or mutation of the SNP in one hundred or more cells provides 
sufficient power to detect up- or down-regulation of expression consistent with most eQTL 
effect sizes.  In a single experiment, we screened 57 SNPs in eQTL intervals of three genes 
associated with inflammatory bowel disease (CISD1, PARK7, and DAP), and showed, with 
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replication and subsequent validation, that in two cases a single SNP located within an 
open chromatin peak is likely responsible for the genetic association.  
 
Figure 3.1 Experimental design of expression CROP-seq screening of eSNPs. (A) 
SNPs were selected with various eQTL p-values from one or two credible intervals for 
each eGene. Additional SNPs in low LD with the credible interval were selected as 
control SNPs. Each SNP was targeted by a single gRNA with minimal predicted off-
target effect. The horizontal black line represents a hypothetical locus with exons 
indicated by solid blocks. (B) The Cas9 editing site may be a few bases away from the 
targeted SNP and can introduce four possible genetic alterations: deletion of both the 
cutting site and target SNP; insertion; deletion of only the cutting site; and mutation of 
the target SNP. (C) Pooled CROP-seq lentiviral libraries with 67 gRNA were transduced 
into the HL60/S4 cell line. Most cells were transduced with a single gRNA. Red, green, 
yellow and blue represent four different gRNAs. A few cells have zero (grey cell) or 
multiple gRNAs. After 10X single-cell RNA-seq identified the gRNA of each cell, 
differential expression of the linked transcript is evaluated between cells with the gRNA 
relative to cells with all other gRNAs. 
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3.2 Materials and methods  
3.2.1 gRNA design and cloning  
Approximately 20 SNPs were chosen for each gene based on prior eQTL mapping 
in peripheral blood mononuclear cells (PBMC)57, along with five positive controls 
targeting the coding regions of the essential genes, TUBB and RUNX1, three negative 
controls that have no perfect target in the human genome, and one non-SNP targeting 
control. Each SNP was targeted for mutation, micro-deletion, or micro-insertion, by one 
single gRNA predicted in silico with COSMID software26 to have a minimal likelihood of 
inducing off-target effects. The chromosomal position of each SNP and the flanking 
sequences were obtained from dbSNP71. All 19-base sequences followed by the correct S. 
pyogenes Cas9 Protospacer Adjacent Motif (PAM) sequence (NGG) inside the window 
were screened. gRNAs with GC rate over 80% or less than 40% were filtered out to ensure 
better cutting performance. The gRNAs with the shortest distance from the cut site to 
targeted SNP (in most cases less than 10 bases) and minimal predicted off-target effects 
were used in our study. All selected gRNAs (listed in online Table S1, 
https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables) have only 
one perfect match to the whole reference genome, and negative controls had no perfect 
match in the human genome.  
The CROPseq-Guide-Puro plasmid42 (Addgene, Watertown MA, catalog number 
#86708, originally from Christoph Bock’s lab) was digested by Esp3I (NEB, R0734S). For 
each designed gRNA sequence, a pair of annealed oligos was cloned into the vector before 
the gRNA scaffold and after the U6 promoter. Clones were pooled for Maxi-prep (Qiagen, 
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Hilden Germany, catalog number #12165) following the manufacturer’s protocol. The 
gRNA distribution in the plasmid prep was validated by next-generation sequencing.  
In order to estimate the nature and rate of editing, single cell clones were generated 
from the same cell population that was transduced by the two lentivirus vectors in 
preparation for scRNAseq. Integrated gRNA sequences of each single cell clone were 
identified by amplifying a 300bp to 400bp fragment surrounding the relevant target SNP 
from 73 single cell clones representing one of 19 individual gRNAs. Next-generation 
sequencing was used to characterize the edited sequences. Online Table S2 
(https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables) reports the 
exact edit in each clone, and shows that 92% of the cells contained at least one edited allele, 
with 29% showing a single edited allele. The remainder either had two different edits, or 
only a single edit (implying biallelic editing, or that the alternate allele was not amplified). 
Additional columns show whether the target SNP was disrupted by a mutation within 3bp 
of the target (67% of all clones) or whether the target SNP was directly disrupted (46%).  
3.2.2 CROP-seq lentivirus library construction and transfection  
Lentivirus production from lentiviral vectors CROPseq-Guide-Puro and lentiCas9-
Blast107 (Addgene, 52962) and was performed following Addgene’s standard lentivirus 
production protocol using the Lenti-X 293T cell line (Takara, Kusatsu Japan, catalog 
number #632180). LentiCRISPRv2GFP108 (Addgene, catalog number #82416) was used 
as the reporter in each transfection. Lentivirus was pelleted by using L-90K ultracentrifuge 
(with SW32-Ti rotor, 25,000 rpm for 1.5 hours at 4 degree) and dissolved in 100 µl 1xPBS.  
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Spinfection of HL60/S4 was performed according to the protocol from Feng Zhang 
lab [16]. Cells were seeded in a 24-well plate at a density of 1×106/ml with 5 μg/ml of 
polybrene (EMD Millipore, Burlington MA, catalog number TR-1003-G). Up to 10 μl of 
concentrated lentivirus was then added to each well, and cells were centrifuged at 1200×g 
for 1.5 hours at 33oC. HL60/S4 cells were first transduced by CROPseq-Guide-Puro 
lentivirus. 24 hours after spinfection, cells were re-plated at a density of 5×105/ml with 2 
μg/ml puromycin (SigmaAldrich, P8833) selection for 8 days or until no viable cells were 
observed. Cell viability was monitored every 24 hours, the media was changed every 48 
hours, and cell density was maintained under 1×106/ml. The multiplicity of infection (MOI) 
was calculated, and the group with the least non-zero MOI was marked as HL60/S4-PuroR 
and used for downstream experiments for achieving optimal single gRNA assignment in 
the cell population.  
After 3 days of recovery in regular culture media, HL60/S4-PuroR was transduced 
by lentiCas9-Blast lentivirus using spinfection with the same protocol as the CROPseq-
Guide-Puro lentivirus transduction. 24 hours after spinfection, cells were plated at a density 
of 5×105/ml with 10 μg/ml blasticidin (Research Products International, Mt Prospect IL, 
catalog number B12200) selection for 7 days. After 3 days of recovery, cells were further 
selected by dual drug selection for 3 days (1 μg/ml puromycin and 5 μg/ml blasticidin) to 
remove residual non-puroR-blastR cells. Cells were then cultured in normal media for 10 
days for global gene expression recovery.  
3.2.3 Single-cell RNA sequencing and data processing  
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Single-cell RNA sequencing libraries were prepared using 10X Genomics 
(Pleasanton, CA) Chromium single cell 3’ reagent kit V2 (PN-120267) and V3 chemistry 
(PN-1000092) with fresh cells for replicate one and replicate two, respectively. The 
average cDNA library size was 484 bp and 505 bp for replicate 1 and replicate 2, 
respectively. Sequencing was performed on an Illumina NextSeq 550 system in high-
output mode, generating paired-end libraries (28bp for read1 and 98bp for read2). Raw 
sequence data was first de-multiplexed from BCL files into FASTQ files by using 
“cellranger mkfastq”, with 10X Cell Ranger software. The human reference genome (hg38) 
was supplemented with 67 gRNA artificial chromosomes, each of which include 241 bp 
U6 promoter sequences, 8 bp gap sequences between U6 promoter and gRNA, 20 bp gRNA 
sequences and 261 bp backbone sequences downstream of the gRNA. This 67 gRNA 
extended hg38 was indexed by “cellranger mkref” with extension “.fa” and “.gtf” files as 
input. Single cell gene counts were generated by “cellranger count” by aligning reads to 
the extended hg38 by STAR aligner76 with default settings. The estimated total number of 
cells detected was 8,671 and 10,087 for replicate 1 and replicate 2, respectively. The 
average total sequencing read depth per cell were 58,413 and 45,636 for replicate 1 and 
replicate 2, respectively.   
Each cell was distinguished by a cell barcode and a gRNA sequence, and in the 
majority of cases a single gRNA was uniquely assigned to each cell (Figure 3.2A). To 
confirm that the scRNAseq profiles adequately represent rates of lentiviral transformation, 
we amplified and sequenced the integrated gRNA sequence from 96 single-cell derived 
CRISPR/Cas9 clones, observing a similar distribution of gRNAs (Figure 3.2B).  
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The count of UMI (unique molecular identifiers) for each gRNA per cell was 
quantified by “cellranger count”. The gRNA-cell expression matrix was extracted from the 
cell-gene expression matrix. Only cells with a single gRNA expressed were included in the 
downstream analysis. If the gRNA UMI count was greater than 0, it was coded as 1, 
otherwise coded as 0. This updated gRNA-cell identity matrix was appended to the cell 
gene expression matrix, providing the gRNA assignment for each uniquely assigned cell.   
 
 
Figure 3.2 Guide RNA distributions.  (A) The distribution of number of gRNA per cell 
detected from scRNAseq. (B)  Similar distributions were observed for amplified gDNA 
insertions in 96 single cell clones. (C) Histogram showing the number of cells containing 
each gRNA in the two replicates. (D) Raw read counts of each gRNA in the pooled 
library with respect to the candidate eSNPs or negative controls. (E) Number of cells 
assigned to each gRNA in scRNAseq shows a similar profile. (F) Log2 ratio of 
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normalized RNA to DNA implying no deviation from expected equivalence, except for 
positive controls in the essential genes RUNX1 and TUBB.  
3.2.4 Expression data quality control and normalization   
The R package Seurat V3.0109 downloaded from https://github.com/satijalab/seurat 
was used for single-cell RNAseq expression data processing and analysis. Low quality 
cells with less than 200 genes expressed as well as lowly expressed genes detected in fewer 
than six cells were filtered out. Next, cells that had between 2,000 to 7,000 expressed UMIs 
and cells having less than 25% mitochondrial counts were retained. After quality control, 
8,192 cells and 16,372 genes were kept for replicate 1, and 8,921 cells and 16,407 genes 
were kept for replicate 2. Then gene expression measurements were normalized by dividing 
by the total UMI counts and multiplying by the scaling factor 10,000, and transformed to 
logarithm base 2.  
Linear dimensional reduction principal component analysis, PCA, was first 
performed with the top 2,000 identified highly variable genes and default settings in 
Seurat109. The “JackStraw” function implemented in Seurat was used to determine the 
significant PCs. Nonlinear dimensional reduction by uniform manifold approximation and 
projection (UMAP)110 was then performed based on the top 20 significant PCs with default 
settings. Each cell was assigned a score summarizing expression of G2/M and S phase gene 
markers implemented in Seurat package, and thereby classified into either G2M, S or G1 
phase according to its cell cycle score. The UMAP projection in Figure 3.3 suggests some 
clustering of cells by cycle identity (f) which also correlates with read depth (e) and number 
of detected genes (d).  However, individual transcripts do not cluster with respect to these 
properties (a-c).  
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Figure 3.3 UMAP visualization of single-cell transcriptome profiles.  Each panel 
shows the UMAP projection implemented in Seurat [18] of the first 20PC of UMI 
abundance variation.  Cells are color coded according to: log2 normalized UMI counts of 
(A) CISD1, (B) DAP or (C) PARK7; (D) number of genes; (E) raw UMI counts detected 
in each cell; and (F) inferred cell cycle state.  The UMAP projection is the same as in 
Figure 3.4A. 
3.2.5 Hypothesis Testing  
While more complex models, for example cell cycle fitting, or matching cells 
according to UMI count, were considered, they did not change the conclusions.  We 
therefor report the simplest statistical approach to hypothesis testing. Each of the candidate 
eSNPs from one credible interval was fit with the normalized expression of its respective 
target eGene. Univariate linear regression was performed with “lm” function in R. 
Student’s t-test was conducted to test the null hypothesis that the coefficient of eSNP equals 
to zero in the regression. Bonferroni correction was applied for the simultaneously 
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performed independent t-tests within each locus, namely alpha = 0.05 divided by 20 tests 
per gene for a gene-wise nominal adjusted critical value of 0.0025.   
3.2.6 Validation in CRISPR edited cells with single gRNAs  
  We further validated the effects of the two identified eSNPs on expression of the 
target genes CISD1 and PARK7 with two single guide RNA approaches. First, HL60/S4 
cells were transduced by lentiCas9-Blast and CROPseq-Guide-Puro lentivirus with the 
same gRNAs targeting rs2251039, rs35675666, or a negative control, using the same 
protocol as described before but as individual gRNAs in three separate transfection 
experiments. DNA was extracted from the bulk edited cells, the targeted regions were 
amplified by PCR, and genotypes assessed by Sanger Sequencing (Eurofins Genomics) 
using the Synthego ICE strategy111. Online Table S4 
(https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables) shows the 
proportions of most commonly edited alleles at the two loci, accounting for 87% of the 
rs2251039 and 79% of the rs3567566 edits.  In both cases the bulk of the edits are indels 
adjacent to the SNP.  Transcript abundance in duplicate bulk RNA extracts was estimated 
by real time quantitative reverse transcription polymerase chain reaction (qRT-PCR). 
Second, these bulk edited cell suspensions were single cell sorted and seeded into 
96-well plates with standard culture media and cultured for 14 days. Half of the cells for 
each single cell clone were taken at day 7 for genotyping using next-generation sequencing 
of the targeted region. From these, a set of single cell clones that expanded successfully 
and had the SNP removed/ affected were chosen for qRT-PCR, including 7 rs22510396 
gRNA-edited clones, 6 rs35675666 gRNA-edited clones, and 4 clones edited with a non-
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targeting negative control gRNA.  The sequences of the targeted alleles are shown in online 
Table S5 (https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables). 
RNA from each selected single cell clone was extracted using a RNeasy Mini Kit (Qiagen, 
cat. no. 74104) and reverse transcribed with iScript™ cDNA Synthesis Kit (Biorad, cat. 
no. 1708891) following standard protocols. Cycle thresholds for CISD1, PARK7, GAPDH 
and ACTB were quantified by qRT-PCR with three technical replicates. The 2-ΔΔCt method 
was used to analyse the qPCR results, in which gene expression in cells with gRNA 
targeting CISD1 or PARK7 was normalized by the average of corresponding expressions 
in negative controls as well as the average of two housekeeping genes.  Similar results were 
obtained with each single control gene. 
3.3 Results 
Multiplex CRISPR/Cas9 editing of myeloid HL60/S4 cells, followed by single-cell 
RNA sequencing (scRNAseq), was used to monitor the impact of candidate regulatory SNP 
disruption on gene expression of three genes in a single experiment. We screened 57 
candidate SNPs along with 10 control SNPs, using lentiviral transfection of a single-cell 
clone of the HL60/S4 myeloid human cell line. Approximately 20 SNPs were chosen for 
each gene based on prior eQTL mapping in peripheral blood mononuclear cells (PBMC)57, 
along with five positive controls targeting the coding regions of the essential genes TUBB 
and RUNX112, three negative controls that have no perfect target in the human genome, and 
one non-SNP targeting control. Each SNP was targeted for mutation, micro-deletion, or 
micro-insertion, by one gRNA predicted to have a minimal likelihood of inducing off-
target effects26. Two lentiviral vectors were used to successively infect HL60/S4 cells, the 
first one encoding both the puromycin resistance gene, and a single gRNA (positioned such 
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that transcripts containing the guide would be captured by RNAseq), the second encoding 
both a blasticidin resistance gene and the Cas9 enzyme. This design facilitates 
identification of which guide(s) from the pool of 67 guides in the transformation mix, each 
single cell has taken up.   
Each cell was distinguished by a cell barcode and a gRNA sequence, and in the 
majority of cases a single gRNA was uniquely assigned to each cell (Figure 3.2A). To 
confirm that the scRNAseq profiles adequately represent rates of lentiviral transformation, 
we amplified and sequenced the integrated gRNA sequence from 96 single-cell derived 
CRISPR/Cas9 clones, observing a similar distribution of gRNAs (Figure 3.2B). The 
distribution of cells per unique guide ranged from 10 to 550, with an average of 117.3 ± 
66.5 cells, ensuring sufficient statistical power to detect eQTL with moderate to high effect 
sizes (Figure 3.2B). Furthermore, each of the 67 gRNAs were evenly distributed in the 
transfection mix of cloned DNA plasmids. There were no significant fold changes in guide 
abundances in scRNAseq relative to DNA plasmid levels, with the exception of the 
essential genes RUNX1 and TUBB (Figure 3.2D, E). These results confirm the efficiency 
of Cas9-mediated editing and imply that disruption of the regulatory regions of the three 
target genes did not compromise cell viability.   
We characterized the transcriptional profiles of 6,358 and 6,974 single gRNA 
assigned cells in two biological replicates, with on average 58,413 and 45,636 sequencing 
reads per cell. Cells with two or more gRNAs were excluded from the eQTL analysis. 
UMAP projection shows that the expression of CISD1, DAP and PARK7 was uniformly 
allocated among the clusters (Figure 3.3A-C). There was some clustering of the cells with 
respect to total number of reads and of UMI, which to some extent correlates with cell 
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cycle stage (G1, S or G2/M) (Figure 3.3D-F), while a small number of low-transcript 
abundance cells were also excluded from further analysis. Figure 3.4A shows that cells 
with a single gRNA (for example targeting to rs2251039) (orange) and cells with gRNAs 
other than the one targeting to rs2251039 (blue) were also evenly distributed with respect 
to the clustering.  
 
Figure 3.4 Identification of causal variants by expression CROP-seq. (A) Nonlinear 
dimensional reduction of 20PCs of single cell transcriptome profiles by UMAP in Seurat 
(18). Cells are color coded as orange rs2251039 gRNA; blue gRNAs other than 
rs2251039; grey without any gRNA. Excluded cells with abnormally low number of UMI 
indicated by the dashed circle. (B, C) Violin plots show kernel density distributions of the 
expression of normalized log2 CISD1 and PARK7 UMI counts of cells with (+) or 
without (-) gRNAs targeting rs2251039 or rs35675666. Boxplots show the median, first 
and third quantiles of the data. (D, E) Chromatin accessibility of identified expression 
CROP-seq peaks for CISD1 and PARK7. Top and middle histograms show HL60 ATAC-
seq (GSM2083754) peaks and HL60 DNase-seq (ENCSR000ENU) peaks, respectively. 
The third panel shows the negative log10 p-value of student’s t-test statistic 
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corresponding to the genomic location of the tested SNPs in two biological replicates, 
with the gene-wise Bonferroni adjusted p-value = 0.0025 threshold indicated by the 
dashed line. The bottom panel is a schematic of all gene transcripts annotated from the 
UCSC gene table (hg38). Red arrows point to the two inferred causal eSNPs in both 
replicates.  
Univariate linear modelling was sufficient to resolve individual eSNP effects 
observed in two replicates of the experiment conducted several months apart.  In the first 
replicate, two SNPs, one in CISD1 (rs2251039), and one in PARK7 (rs35675666) were 
identified as putatively causal (p<10-6 and p< 10-20; both with Bonferroni corrected p-
value < 0.0025). The same two SNPs replicated in the second experiment, at similar 
significance levels (Figures 3.4B, C). Only two other nominally-significant associations 
were observed, in a single replicate at DAP and a single replicate at CISD1. Moreover, 
we also examined if the knockout or mutation of targeted SNP would also influence the 
expression of adjacent genes. We tested the association between CISD1 eSNPs with 
IPMK or UBE2D1 expression, as well as between PARK7 eSNPs and ERRFI1 (TNFRSF9 
abundance was too low to assess), and between DAP eSNPs and ANKRD33B expression. 
None of the candidate eSNPs showed significant association with the nearby transcripts 
in either replicate (online Table S3, 
https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables).   
Both of the significant SNPs were also among the most significant hits in the CAGE 
study that motivated sampling of the three genes57. Further evidence that they are likely 
causal is provided by the observation that they both lie under chromatin accessibility assay 
peaks. Figures 3.4D, E show the location of each assayed SNP at CISD1 and PARK7 
relative to ATACseq and DNase-seq (ENCSR000ENU) profiles of HL60/S4 cells113. The 
majority of the nonsignificant expression CROP-seq SNPs lie between ATAC or DHS 
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sites. Furthermore, rs2251039 is located just 28bp upstream of the transcription start site 
of CISD1 and is within a binding motif for the Bhlhe40 transcription factor, a known 
regulator of cytokine production in T-cells114.  
The function of both SNPs was validated using qRT-PCR on both bulk edited cells 
and in single cell clones, with results illustrated in Figure 3.5. Bulk transfection of HL60 
cells with single guides resulted in down-regulation of the associated CISD1 and PARK7 
transcripts relative to cells transfected with non-targeting control gRNAs to a similar 
degree as inferred in the expression CROP-seq assays.  More precise evidence for down-
regulation of gene expression after disruption of the targeted SNP was obtained by qRT-
PCR of 6 single cell clones containing indels in or adjacent to rs35675666 in PARK7, or 7 
single cell clones containing indels in or adjacent to rs2251039 in CISD1. Relative to 
expression in 4 non-targeting control clones and normalized to the unaffected 
housekeeping genes GAPDH and ACTB with the 2-ΔΔCt method115, all targeted transcripts 
showed between 20% and 87% reduced abundance, with p<0.005 for both genes.   
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Figure 3.5 Targeted gene expression change of CRISPR-edited cells with single 
gRNA.  qRT-PCR was performed on both bulk CRISPR-edited cells (A) and single cell 
clones (B) with gRNAs targeting rs35675666 (gRNA1, PARK7) and rs2251039 (gRNA2, 
CISD1) respectively.  Cycle threshold (Ct) values were normalized relative to 4 
biological replicates with cells expressing Cas9 and a non-targeting gRNA using the 2-
ΔΔCt method [24]. The expression of the transcript associated with each targeted SNP was 
reduced in both qRT-PCR designs, with significance (one tailed t-test of deviation of 
estimated fold reduction relative to unity) indicated by the indicated p-values: bulk-
gRNA1, p =0.02; bulk-gRNA2, p=0.05; single cell clone gRNA1 p=0.0004; single cell 
clone gRNA2, p=0.0015. 
3.4 Discussion 
Published genome-editing strategies for interrogating regulatory elements either 
utilize CRISPRi or CRISPRa to inhibit or activate transcription43,116, or rely on assays that 
select for essential gene function36,37,106 or reporter gene expression94. Neither approach is 
suitable for systematically screening the function of each of the candidate SNPs in a 
credible interval of a typical gene.  Massively parallel reporter assays have been used to 
this end more successfully.  For example, Van et, al32 evaluated 32,373 variants at 3,642 
eQTL by inserting 180bp oligonucleotides encompassing each SNP in front of a minimal 
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promoter, finding 842 polymorphisms that drive reporter expression in a lymphoblast cell 
line at different levels.  An even larger scale experiment by van Arensbergen et al32 
surveyed 5.9 million variants, namely 57% of all known common variants in the human 
genome, by associating short DNA fragments with a barcode and assaying tag abundance 
in hepatic and erythroid cell lines. They identified over 30,000 candidate eSNPs, most cell-
type specific, and described enrichment with various chromatin features.  Impressive as 
these studies are, there is always the caveat that enhancer activity outside normal chromatin 
context may not be accurate, and perusal of the SuRE database32 suggests that many sites 
have large but nonsignificant effects since the majority of the cloned fragments do not drive 
expression.  Hence, false negative rates are not known, and complementary assays that 
systematically interrogate credible intervals in the same promoter context should also be 
informative.  
Our approach is to directly measure expression of a gene after genome-editing of 
a set of regulatory polymorphisms.117 Targeted reporter assays analyzing RNA from bulk 
preparations of clonal cell lines, have low power to resolve typical eQTL effects that 
explain in the range of 10% to 20% of the variance of the target gene. The CROP-seq 
single-cell eQTL screening strategy gains power from the sequencing of thousands of 
cells in parallel. The effect size of rs2251039 in CISD1 corresponds to a reduction of 
around 0.5 standard deviation units due to gene editing, equivalent to an eQTL explaining 
between 5% and 10% of the variance (depending on the allele frequency and assumptions 
about whether one or both alleles are disrupted in the CROP-seq). The much larger 
rs35675666 effect at PARK7 could correspond to a three-times larger-effect eQTL, or 
may reflect more efficient gene editing by the particular gRNA, which appears to create 
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large deletions encompassing the SNP (online Table S2, 
https://github.com/RuoyuTian/PhD_thesis/tree/master/chapter3_supp_tables).  
Interestingly, rs35675666 is located in the first intron of the PARK7 transcript and 
is a GWAS SNP for ulcerative colitis (p-value = 5×10-9) and inflammatory bowel disease 
(p-value =1×10-15)117. Although McCole et, al118 argued that ERRF11 is a strong candidate 
gene in the interval due to the impact of ErbB receptor feedback inhibition on epithelial 
apoptosis and possibly barrier function, the absence of effect on ERRF11 transcript 
abundance calls into question that inference and instead promotes PARK7 as the likely 
causal gene. PARK7 encodes a C56 peptidase family member that has been shown to 
function as a regulator of mitochondrial respiration and lysosomal function119. Autosomal 
recessive loss of function leads to early-onset Parkinson’s disease, and reduced expression 
may conceivably disrupt autophagy or oxidative stress sensing, both of which are 
implicated in ulcerative colitis120. 
In theory, expression CROP-seq should be powered to fine map eSNPs within 
credible intervals that explain just a few percent of the expression of a target gene. We 
were able to confirm the identity of autoimmune disease-associated GWAS variants in two 
loci, but did not detect the third eQTL or resolve the secondary associations that are 
nevertheless present at each of the loci we tested. Comprehensive fine-mapping will often 
require 100 or more gRNAs per gene, but is well within the scope of the experimental 
pipeline described here. Limitations include the inability to target all SNPs due to absence 
of appropriate PAM sequences, reduced power for genes expressed at levels close to the 
limit of detection in scRNAseq, and appropriateness of the cell line(s) chosen for the assay. 
Replication is likely to be important for the confident identification of relatively small 
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effect eSNPs, particularly given that cell passaging, mutation, and random variability 
during cell culture can affect the transcriptional background91.  Future experiments may 
also use prime editing121 to specifically replace one allele with the alternate allele, rather 
than inducing mutations at or near the site. Finally, we also show that integration with 
functional annotation data may help to validate inferred eSNPs and identify the likely 
transcription factors they bind. In all, our method facilitates the genetic screening of non-
coding variants and the transcriptional interpretation of risk variants in the post-GWAS 
era.   
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CHAPTER 4. CLASSIFYING THE TOLERANCE OF 
PROMOTER REGIONS BY THE BURDEN OF RARE 
VARIANTS ACROSS TISSUES 
ABSTRACT: A large majority of genetic variants are rare in the population, some 
unknown fraction of which may have large regulatory effects through which they 
contribute to disease risk. However, the study of rare variants lags behind common variants, 
in part due to the insufficient sample size of risk alleles. Importantly, some of these may 
also be responsible for observed common variant effects, due to synthetic association with 
disease risk in GWAS. Moreover, investigation of the functionality of rare variants across 
individual tissue types has just started.  Here, I used GTEx V8 data from 740 European 
individuals across 49 tissues to show that there is enrichment of rare alleles in the promoter 
regions of individuals who have extreme expression across tissues.  The rare allele burden 
gradually weakens with distance from the TSS. Moreover, significant depletion of rare 
allele associated with extreme expression is observed in loci with low relative promoter 
polymorphism across tissues. From these observations, I develop a novel gene 
categorization system that annotates genes according to the degree of intolerance to 
regulatory rare variants and relative regulatory region polymorphism. Genes that are 
intolerant to rare regulatory mutation and has constraint in regulatory region are informed 
with tissue cluster, implying its potential application in updating the existing regulatory 




 Rare mutations make a major contribution to disease risk for individual people. 
However, rare variant associations cannot be detected by GWAS due to the insufficient 
sample size of the risk allele. On the other hand, rare risk alleles may be responsible for 
common variant GWAS associations if there is “synthetic association” between multiple 
rare risk alleles and a GWAS-tagged common SNP. In these cases they will usually go 
undetected. A handful of recent studies have shown that rare variants are nevertheless 
associated with extreme gene expression in peripheral blood and other tissues102,122. 
Notably, the Bayesian framework algorithm RIVER (RNA-informed variant effect on 
regulation) integrates functional genomics data to compute the probability that a given rare 
variant has a regulatory impact122, prioritizing the regulatory rare variants as likely causal.  
 Current approaches utilize exome sequencing data and evolutionary constraint 
estimates to develop scoring systems that quantify genic intolerance to mutation123-125. By 
comparing the expected with observed PTV (protein-truncating variants) of each gene from 
whole exome sequencing data, genes are classified into null, recessive and 
haploinsufficient. One corresponding score, pLI, quantifies the probability of being loss-
of-function intolerant123. Genes with pLI ≥ 0.9 are intolerant to loss-of-function mutation, 
while genes with pLI ≤ 0.1 are tolerant to loss-of-function mutations. A similar genetic 
score RVIS (Residual Variation Intolerance Score) takes the studentized residual of a 
regression of the number of missense and truncating variants on the sum of all variants, but 
is restricted to protein coding regions125. Genes with negative RVIS are intolerant to 
functional variations, and are enriched in OMIM. Furthermore, a similarly calculated score 
ncRVIS (noncoding RVIS), compares the predicted and observed prevalence of regulatory 
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variants, and performs well in predicting dosage sensitive genes124. However, none of those 
scores use the non-coding region rare variants and evolutionary constraint measures to 
categorize genes, and have not emphasized tissue specific disease-associated genes.  
 Here, I performed a regulatory rare variant burden test on the large GTEx dataset 
with 740 European individuals including both RNA sequencing, and whole genome 
sequencing data across 47 tissues and 2 cultured cell lines. I used this data to develop a 
novel gene categorization system that systematically places genes into tissue clusters 
according to the degree of intolerance to regulatory rare variants and the relative regulatory 
region polymorphism. I compare the new score to pLI and RVIS and show that it provides 
an alternative method for prioritizing rare promoter variants as potentially causal. 
4.2 Materials and methods 
4.2.1 Dataset 
I used sequencing data from the current release version 8 of the Genotype-Tissue 
Expression (GTEx) project. Samples were collected from 54 non-diseased tissue sites 
sampled at autopsy from 980 deceased individuals. RNA-seq, WES and WGS was 
available. RNA-seq data were downloaded from the GTEx portal fully processed, filtered 
and normalized, as used for eQTL analysis by the GTEx consortium126. Out of 980 
individuals, 866 individuals had WGS data, and after filtering out non-European ancestry 
individuals to avoid complications of population stratification, 740 individuals were 
retained. 47 tissues and 2 cultured cell lines were included in the analysis.  The number of 
samples with both RNA-seq and WGS data for each tissue is summarized in Table 4.1.  
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Table 4.1 GTEx V8 tissues and samples with both RNA-seq and WGS data 
Tissue Sample size Tissue 
Sample 
size 
Adipose Subcutaneous 492 Esophagus gastroesophageal junction 281 
Adipose visceral omentum 402 Esophagus mucosa 424 
Adrenal gland 200 Esophagus muscularis 396 
Artery aorta 338 Heart atrial appendage 322 
Artery coronary 180 Heart left ventricle 334 
Artery tibial 489 Kidney cortex 65 
Brain amygdala 119 Liver 183 
Brain anterior cingulate cortex 
BA24 136 Lung 444 
Brain caudate basal ganglia 173 Minor salivary gland 118 
Brain cerebellar hemisphere 158 Muscle skeletal 602 
Brain cerebellum 189 Nerve tibial 449 
Brain cortex 184 Ovary 140 
Brain frontal cortex BA9 158 Pancreas 252 
Brain hippocampus 151 Pituitary 220 
Brain hypothalamus 157 Prostate 186 
Brain nucleus accumbens basal 
ganglia 182 
Skin not sun exposed 
suprapubic 440 
Brain putamen basal ganglia 154 Skin sun exposed lower leg 518 
Brain spinal cord cervical c-1 115 Small intestine terminal ileum 144 
Brain substantia nigra 101 Spleen 185 
Breast mammary tissue 337 Stomach 269 
Cells cultured fibroblasts 416 Testis 277 
Cells EBV-transformed 
lymphocytes 116 Thyroid 494 
Colon sigmoid 273 Uterus 108 
Colon transverse 305 Vagina 122 
  Whole blood 574 
4.2.2 Rare variants burden test  
Rare variants are defined as variants with minor allele frequency smaller than 0.05 
and were extracted from the WGS genotype data. If a gene has multiple transcripts, the 
transcription start site (TSS) was set as the most upstream TSS. For all analysis, I 
heuristically defined the promoter region as TSS±1𝑘𝑘𝑘𝑘. Rare variants located in other 
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regulatory regions were also extracted for some analyses, including 20-21 kb, 10-11 kb, 5-
6 kb, 3-4 kb regions upstream of TSS, or 3-4 kb, 5-6 kb regions downstream of TSS. 
Regulatory region rare variants genotypes were available for 17, 158 genes, excluding the 
HLA gene complex, from 740 European individuals.  
 The burden test conducted here was introduced explicitly in Zhao et, al102. In brief, 
for each gene, the transcript abundance of each gene in each individual was sorted into bins 
according to rank of relative expression. Each bin has 6 individuals. Number of expression 
bins vary in tissues depending on sample size. For each bin of each gene, the number of 
rare alleles in a specified regulatory region of individuals in that bin was counted, and the 
sum of rare allele counts for each bin over all 17,158 genes was computed.  Typically, this 
results in a “smile plot” where the counts are highest in the bottom and top percentile bins, 
implying an excess burden in individuals with extreme expression. To evaluate the 
relationship between rare variants in regulatory region with expression statistically, a linear 
quadratic regression analysis 
𝑦𝑦 = 𝛽𝛽0 + 𝛽𝛽1𝑥𝑥 + 𝛽𝛽2𝑥𝑥2 + 𝜀𝜀    (1) 
was performed by fitting the numeric expression bin order (𝑥𝑥) with the summed rare allele 
counts (𝑦𝑦) in corresponding bins, where 𝛽𝛽0,𝛽𝛽1,𝛽𝛽2 are the coefficients, 𝜀𝜀 is the random 
error which is assumed to be normally distributed with a mean of zero. The burden tests of 
rare variants were performed for the 49 tissues.  Subsequently, within each tissue, tests 
were performed with rare variants in the previously specified seven regulatory regions at 
increasing distances from the TSS.  
4.2.3 Computation of nucleotide diversity  
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   Nucleotide diversity is defined as the average number of nucleotide differences per 
site between two randomly chosen DNA sequences, denoted by 𝜋𝜋, 
𝜋𝜋 = ∑ 𝑥𝑥𝑖𝑖𝑥𝑥𝑗𝑗𝜋𝜋𝑖𝑖𝑗𝑗𝑖𝑖𝑗𝑗 , 
where 𝑥𝑥𝑖𝑖 and 𝑥𝑥𝑗𝑗  is the frequency of the 𝑖𝑖th and 𝑗𝑗th sequence in the population, respectively, 
𝜋𝜋𝑖𝑖𝑗𝑗  is the number of nucleotide differences per nucleotide site between the 𝑖𝑖th and 𝑗𝑗th 
sequence127. I computed the nucleotide diversity by VCFtools128 with 740 European 
individuals WES and WGS genotypes. To compute the coding region nucleotide diversity, 
𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐, I used WES data of 5,430 genes. To compute the promoter region nucleotide diversity, 
𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 , I used the WGS data of 17,153 genes, and the promoter region is defined as 
TSS±1𝑘𝑘𝑘𝑘.  
4.3 Results 
4.3.1 The burden of rare variants in extreme expression across tissues  
 Significant quadratic linear regressions of fitting expression bin (𝑥𝑥) to number of 
rare variants in individuals (𝑦𝑦) were initially observed in peripheral blood samples of 472 
genes from 410 individuals102. Similarly, using a different methodology, burdens were also 
observed in GTEx v6 data for 449 individuals across 44 tissues for rare regulatory variants 
in 10kb TSS region for outlier expression both in single and multiple tissues122. 
I systematically performed the burden test with data for 740 individuals and 49 
tissues from GTEx v8 RNA-seq and whole-genome sequencing data, performing each test 
across tissues over regulatory regions in 1kb-sliding windows. The “smile” plots in Figure 
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4.1 show enrichment of rare variants in individuals in the extremes of either high or low 
expression. Each incremental step towards low or high expression is the first order of 
expression bin (𝑥𝑥) plus a constant, the coefficient of 𝑥𝑥 in the regression (1). A significant 
quadratic relationship is observed for most of the tissues in each of five tissue clusters (see 
explanation in section 4.3.4). GTEx v8 data provides sufficient sample size for all tissues. 
There is no correlation between sample size (Figure 4.2a) or significance (Figure 4.2b, c, 
d), and the enrichment of rare variants within 2kb region of TSS shows in most tissues 
(Figure 4.2b, e).  
 
Figure 4.1 Linear quadratic regression of rare allele counts and expression bin. 
Scatter plots show promoter region (TSS ± 1𝑘𝑘𝑘𝑘) rare allele (MAF < 0.05) counts (y) for 
the corresponding expression bin (x). A fitted linear quadratic regression line is drawn 
with grey shade showing standard error of prediction. A tissue with significant fitting in 
each of five tissue cluster is shown: (a) brain hippocampus for B cluster; (b) pituitary for 
E cluster; (c) esophagus muscularis for C cluster; (d) skin sun exposed lower leg for O 
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cluster; (e) testis for T cluster. The p-value of each model is reported on the plot 
accordingly.   
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Figure 4.2 Summary of burden tests across tissue and regulatory regions.  (a) 
Circular barplot shows tissues and sample size (Table 4.1) used for burden tests, colored 
by tissue clusters, B, E, I, O and T. (b) Significance (negative log10 p-value) of each 
burden test in each tissue within 2kb TSS, or in the regions (c) 5-6 kb upstream and (d) 
downstream of the TSS. The red dashed line is the significant level (𝛼𝛼) at 0.05, 
− log10 𝛼𝛼 = 1.3. (e) Barplot shows the number of significant regressions at each region 
around TSS across tissues. The width of each bar is equal to the width of sliding window.  
The magnitude of enrichment decreases as the 1kb sliding window moves away 
from TSS (Figure 4.2c, d), and there are fewer tissues showing the enrichment. However, 
the burden of distant rare variants, located within 20-21 kb upstream of TSS, is still 
observed in 18 tissues (Figure 2e). These results confirm that the rare variants near the 
promoter are likely to lead to extreme gene expression values, and that in some cases distal 
enhancer sequence also show a more modest impact. It is interesting that the O cluster has 
the largest number of tissues showing in rare regulatory enrichments, whereas the B (Brain) 
cluster has the minimum. In summary, the burden of rare variants in the TSS region is 
detected in most of the 49 tissues, and the regulatory rare variants are enriched most heavily 
in regions close to the TSS. 
4.3.2 The linear correlation of coding and promoter region nucleotide polymorphism 
 To quantify the genetic variation of regions in genes, I computed the coding region 
nucleotide polymorphism (𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐) for 5,430 genes from WES data, and the promoter region 
nucleotide polymorphism (𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 ) for 17,153 genes by WGS data of 740 European 
individuals, where promoter region is defined as within 2kb of TSS. By merging the two 
sets of nucleotide polymorphism, 5,416 genes with both 𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐 and 𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 were retained for 
analysis. The linear regression (Figure 4.3) fitting 𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐  to 𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 is highly significant with 
p-value = 9.4e-6, and can be described as 
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𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 = 0.04 + 0.04𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐 + 𝜀𝜀        (2) 
The coefficients were estimated using the “lm” function in R. The positive intercept 
indicates that there is an excess of genetic polymorphism in promoter regions relative to 
adjacent coding regions. Moreover, only 3 genes have zero 𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝, whereas multiple genes 
have zero coding region nucleotide polymorphism.  
 The residual of the fit of 𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 𝑜𝑜𝑜𝑜 𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐was extracted for each gene, representing 
the relative genetic diversity. Genes with the top five positive residuals indicating greater 
promoter polymorphism are MUC12, TRBV5-6, ALG1L2, LINC02014 and HLA-DPA1, 
labelled in grey in Figure 4.3. MUC12 encodes a component of the epithelial protective 
barrier and as associated with colorectal cancer. The HLA region is involved in immune 
defense and is known to be highly polymorphic. Genes with the bottom five negative 
residuals are RP11-809H16.5, RP13-131K19.2, KC6, AC008079.10 and RP11-64K12.9, 
which coding regions are unconstrained. Functional enrichment analysis of additional 
genes can be explored further.  
 89 
 
Figure 4.3 Linear relation between coding region and promoter region (TSS±𝟏𝟏𝟏𝟏𝟏𝟏) 
nucleotide diversity. Each dot represents one of 5,430 genes. The red dashed line is the 
fitted regression line according to the model in (2). The red dots are genes with the 
bottom 10% regression residuals indicating the highest level of relative promoter 
constraint. Logarithm transformed scatter plot is embedded in the right upper corner, and 
genes with either 𝝅𝝅𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑or  𝝅𝝅𝒄𝒄𝒑𝒑𝒄𝒄 or both equal zero are removed.  
4.3.3 Genes with low relative polymorphism of promoter to coding are intolerant for rare 
regulatory variants 
Next, I asked whether rare regulatory variants are depleted in genes with relative 
low promoter polymorphism. I performed one-tail unpaired student’s t-tests across all 
tissues. Genes in the bottom 10% of the residual of regression (1) are significantly depleted 
for rare promoter region (within 4kb of TSS) alleles (MAF<0.05) that are also in the top 
and bottom 5% of expression bins. This significant regulatory variant depletion was 
observed for all 49 tissues (Table 4.2).   
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Table 4.2 p-value of unpaired one tail student’s t-test, contrasting the mean number 
of rare alleles (MAF<0.05) in top and bottom 5% extreme expressed individuals 
against all other genes also in the bottom 10% residual of fitting equation 2. 
Tissue p-value Tissue p-value 
 Adipose subcutaneous   2.40e-12 Esophagus 
gastroesophageal junction   
7.06e-14 
Adipose visceral omentum   1.12e-11 Esophagus mucosa   6.28e-16 
Adrenal gland   6.59e-17 Esophagus muscularis   4.73e-15 
Artery aorta   4.00e-16 Heart atrial appendage   1.34e-13 
Artery coronary   1.10e-14 Heart left ventricle   1.19e-15 
Artery tibial   6.36e-17 Kidney cortex   1.49e-12 
Brain amygdala   5.51e-18 Liver   2.58e-16 
Brain anterior cingulate 
cortex BA24   
8.12e-19 Lung   6.03e-18 
Brain caudate basal ganglia   3.74e-18 Minor salivary gland   1.62e-08 
Brain cerebellar hemisphere   2.83e-19 Muscle skeletal   3.64e-13 
Brain cerebellum   3.37e-18 Nerve tibial   8.57e-19 
Brain cortex   4.77e-15 Ovary   2.30e-13 
Brain frontal fortex BA9   4.77e-20 Pancreas   4.49e-10 
Brain hippocampus   6.57e-18 Pituitary   2.08e-17 
Brain hypothalamus   1.19e-16 Prostate   2.75e-14 
Brain nucleus accumbens 
basal ganglia   
4.86e-18 Skin not sun exposed 
suprapubic   
1.31e-18 
Brain putamen basal ganglia   1.37e-07 Skin sun exposed lower leg   1.85e-20 
Brain spinal cord cervical c-1   2.38e-11 Small intestine terminal 
ileum   
2.13e-14 
Brain substantianigra   2.97e-10 Spleen   5.90e-16 
Breast mammary tissue   6.09e-21 Stomach   3.74e-15 
Cells cultured fibroblasts   2.11e-17 Testis   2.39e-28 
Cells EBV-transformed 
lymphocytes   
4.73e-08 Thyroid   4.72e-18 
Colon sigmoid   4.20e-14 Uterus   7.16e-11 
Colon transverse   1.61e-14 Vagina   5.39e-16 
  Whole blood   2.09e-19 
4.3.4 A novel gene classification based on tissue-specific regulatory tolerance 
Zhao et, al observed that genes not represented on the MetaboChip are significantly 
more likely to be enriched for rare regulatory variants102.  Here I propose that disease-
associated genes or highly conserved genes are depleted for rare regulatory variants in 
promoter regions.  Since variants with MAF = 0.01-0.05 are not strongly subject to 
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purifying selection, I chose a more constrained see of rare variants with MAF < 0.01 for 
the following gene classification. By plotting the residual of the fitting of 𝜋𝜋𝑐𝑐𝑐𝑐𝑐𝑐  to 𝜋𝜋𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝 
against the ratio of rare variants in either the bottom or top 5% of extreme expression 
individuals to the total number of rare variants in the promoter region, I divided genes into 
four quadrants: set I, low residual and low ratio; set II, low residual and high ratio; set III, 
high residual and high ratio; set IV, high residual and low ratio. The decision boundary 
reported here is 𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 = −0.025 and 𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑜𝑜 = 𝑝𝑝𝑟𝑟𝑟𝑟𝑟𝑟𝑐𝑐
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 but similar results are seen with 
residual = 0 and the mean ratio.  I hypothesized that set I genes would be depleted of 





Figure 4.4 Hierarchical clustering of tissues by the presence of set I genes. The 
presence and absence of genes in tissue is color coded by purple and white. Side color bar 
annotates tissue cluster B, E, O, I and T. 
 
Figure 4.5 Histogram of set I gene distribution across tissues. 
 
Figure 4.6 Heatmap of the medium expression of set I genes across tissues. Gene 
expression is normalized by row. Side color bar show five tissue clusters. 
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There were 841 genes across 49 tissues in set I. Each gene was coded as 0, not present, 
or 1, present in set I of a particular tissue. Tissues with 841 features are clustered by 
hierarchical clustering in Figure 4.4, which defines five tissue clusters: Brain (B), Endocrine 
(E), Internal (I), Other (O) and Testis (T). It is interesting that all of the brain tissues are 
clustered together in B which has the most genes, consistent with selection against regulatory 
variation in genes that play key roles in normal brain function.  “Testis” is an outlier, 
indicating that regulatory constraint is independent of all other cluster. Set I genes are 
observed on average in approximately 20 tissues, while 55 genes are tissue-specific (Figure 
4.5). The set I genes have relatively low expression in cluster B, are highly expressed in 
testis, and vary in abundance in the other clusters (Figure 4.6). 
4.3.5 Comparison with other tolerance scores 
Two other widely used genetic scores, pLI123 and RVIS125, quantify the probability 
of intolerance to mutation. I also compared the pLI and RVIS score of genes that are 
enriched in 80% of tissues in each tissue cluster, with the exception of testis. Kruskal-
Wallis non-parametric ANOVA tests were applied, none of which showed significant co-
occurrence of different groups of enriched genes, implying that my classification is 
orthogonal to the existing scores. A possible reason is that both of them utilize genetic 
variation in the coding region for computation of the scores. A fourth score was recently 
described by the same group that developed RVIS, designed to identify tolerance to 
variation in distal enhancer elements, which reported a similar result.  The observation that 
my classification by the relative polymorphism of promoter region and coding region, and 
depletion of regulatory rare variants, leads to meaningful clustering by tissue type implies 
there is novel potential for annotating tissue-specific likelihood of regulatory effects.  
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4.4 Discussion  
 In this chapter, I demonstrate that rare variants in the promoter region are regulatory 
and have large effects leading to enrichment in individuals with extreme values of gene 
expression. Integrating these observations with measures of nucleotide diversity, I next 
demonstrate that rare regulatory alleles with large effect are depleted in genes that are 
evolutionary constrained specifically in the promoter region. Filtering genes with relatively 
low promoter nucleotide polymorphism and rare variant depletion by tissue leads to 
categorization of tolerance to mutation which appears to be organized into functional tissue 
groups.  
 Other sets of genes may also be interesting to investigate. For example, set II genes 
are evolutionary constrained in promoter regions but have relative high abundance of rare 
regulatory variants of large effect. Those rare variants maybe not selected against, and are 
less likely to show association with disease risk.  Another interesting analysis would be 
family-based studies of rare diseases, evaluating segregation of rare risk alleles with large 
effect size.  
 In terms of relative expression level of set I genes in tissues, it is interesting that 
brain tissues have relatively low expression levels, whereas testis has the most abundant 
transcript abundance. I did not explore the possible reasons here, but it would be 
worthwhile to analyze case/control expression data of neuronal diseases and ask if those 
enriched genes are differentially expressed genes in specific disease contexts.  
 In summary, the study develops a unique tissue-gene categorization system based 
on quantifying the genic intolerance to rare variants that have large regulatory effect in 
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promoter regions.  As more datasets associating gene expression and rare genetic variation 
with disease appear, it should be possible to develop a validated tool that prioritizes 
regulatory variants for experimental validation of their role in pathogenesis using the 
methods developed in Chapters 2 and 3. 
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CHAPTER 5. CONCLUSION AND DISCUSSION 
 This thesis focuses on experimental and computational functional validation of 
disease-associated risk variants, which is a major challenge of human genetics in the post-
GWAS era. My contributions include design of a CRISPR/Cas9 based regulatory variant 
fine-mapping approach, and development of a gene-tissue categorization system to 
prioritize pathogenic rare variants that are candidates for genetic screening.  
Firstly, I performed a regulatory variant identification assay in CRISPR/Cas9 
genome edited single-cell clones. I observed constraints from the variability in mutability 
of targeted regulatory sites; clonal variability; high expense and low statistical power. This 
led me to conclude that this single-cell clone based method is not recommended for 
scanning within credible intervals of 100 or more SNPs. Secondly, I designed an expression 
CROP-seq method, a CRISPR/Cas9 pooled genomic screening with massively parallel 
single-cell RNA-seq as readout. With expression CROP-seq, mutagenesis was introduced 
simultaneously targeting 60 SNPs of interest to cells with the same genetic background, 
and transcript abundance was quantified at the same time by robust single-cell RNA-seq. 
It largely reduced the impact of some of the sources of variability found in the previous 
method, and greatly enhanced statistical power. Expression CROP-seq comprehensively 
fine-maps eSNPs within credible intervals that explain just a few percent of the expression 
of a target gene. A direct outcome of utilizing this approach was the successful 
identification of two causal regulatory SNPs that altered IBD associated risk gene 
expression, which also reside in open chromatin regions. Subsequently, I aimed to extend 
the application of this approach to rare variants screening. I categorized genes by their 
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tolerance of promoter region and quantity of rare regulatory variants with large effect 
across 49 tissues with GTEx v8 dataset. Genes constrained by promoter polymorphism and 
having deficit of rare regulatory variants are clustered by tissue, which supports the use of 
tissue-gene genomic annotation for prioritization of GWAS tagged risk loci in functional 
validation. 
 Some limitations of CRISPR/Cas9 technology bring up constraints of the 
demonstrated screening approaches. The first constraint is accessibility. The Protospacer 
Adjacent Motif (PAM) sequence (NGG) should be always 3-4 bp downstream of the cut 
site. In my gRNA design, the cut site was restricted to less than 10 base away from target 
SNP, yet even then not all of the SNPs within a Bayesian credible set were editable. For 
example, the top SNP of the primary signal of CISD1, rs146577551, is not targetable. Thus, 
the important finding that multiple independent eQTL regulates gene expression55,56,105,129 
cannot be tested in for all eGenes. The second issue is off-target effects. I chose gRNAs 
with minimal predicted off-target sites throughout entire genome. Off-target effect can be 
minimized by improving off-target prediction algorithms in silico, using optimized 
reagents and controlling Cas9 delivery time130,131. Even though off-target effects are a 
major concern in gene therapy, they should also be considered in genetic screening 
applications. The third constraint is DNA repair pathway. To enhance editing efficiency, I 
chose non-homologous end joining (NHEJ) based pathway to introduce microindels to the 
cut site, instead of homology-directed repair (HDR). In theory, NHEJ reaches high editing 
efficiency up to 20%-60%24, while HDR is only 0.5%-20%. Even though it would be ideal 
to replace the reference allele with an alternate allele by HDR with an introduction of 
template DNA, I utilized NHEJ out of consideration of editing efficiency and power. In 
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my case, NHEJ achieved incredibly high editing efficiency, 90% on average. Causal eSNPs 
identified by expression CROP-seq are thought to alter gene expression by changing 
transcription factors and regulatory element binding affinity. eSNPs altering gene 
expression by other mechanisms would not be amenable to be identified by expression 
CROP-seq. An emerging technique in CRISPR/Cas9 field, prime editing121, may help to 
improve precision. Prime editing obtains 20%-50% editing efficiency, comparable with 
NHEJ. An advantage of prime editing is that it is able to mediate targeted insertions, 
deletions and all 12 base-base conversions, including four transition mutations and eight 
transversion, without introducing double strand breaks and template DNA.  Thus, prime 
editing both achieves high editing efficiency and replaces alleles on targeted sites, which 
could be a modification for expression CROP-seq.  
 Even though targeted genes I selected were all with medium to high expression in 
HL60/S4, and the identified two causal SNPs downregulated target gene expression after 
editing, I expect that expression CROP-seq is also able to identify those SNPs with 
upregulatory effects. This would be an advantage over MPRA33, which only detects 
regulatory elements that are required to increase reporter expression. Another advantage of 
CROP-seq is that the gRNA sequence itself serves as barcode. Other pooled CRISPR 
single-cell RNA-seq screening methods, like Perturb-seq40, all rely on sequencing the 
barcode to identify individual cells. A potential problem is misidentified cell edits caused 
by frequent recombination of barcode and gRNA. The barcode is always designed to be 
several kilobases from gRNA. During viral infection, it is feasible that barcode mismatches 
with the unpaired gRNA, with a recombination rate that may be as high as 50%. 
Researchers need to pay extra attention when applying such methods132. 
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Cancer genomes can be highly instable. For example, some cancer cell lines have 
big loads of mutations and copy number variation. If SNPs of interest have more than two 
copies, the effect size can be overestimated in the cell line relative to those estimated in an 
eQTL study. One the other hand, if the SNP of interest has only one copy or zero copies in 
a cell, the estimated effect size is underestimated or completely undetectable in the cell.  
Some screening results may be biased.  
 As previously discussed, a meaningful proportion of eQTL are cell-type and tissue-
specific. The importance of validating eSNPs in relevant cell types is now clear, which also 
helps to explain the nature of GWAS signals. Applying expression CROP-seq in primary 
T cells should generate fruitful results for immune associated eQTLs, for example. One of 
the major concerns is the potential variability of genetic background in different batches of 
primary T cells. Since they are isolated from individuals, there might be variation 
introduced by the transcriptional background. It will be necessary to estimate such variation 
before genome editing. On the other hand, we can also treat it as an advantage for the 
application of disease specific loci screening. For example, targeted SNPs in primary T 
cells from IBD patients and healthy controls may have different effects. This application 
will be able to identify context dependent regulatory SNPs, which might be associated with 
the pathogenesis of autoimmune diseases. A successful study using CROP-seq in primary 
T cell is available for reference133. 
 Gene-tissue classification can also be extended for population specific categorizing 
systems. In chapter 4, only European individuals were included in my analysis, and about 
100 non-Europeans were excluded due to low sample size. Rare alleles exhibit variable 
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effect contributions to rare diseases among populations134. The analysis could be applied 
to other populations with sufficient divergent genomic data. 135.  
 RIVER improves rare regulatory variants prediction by using both outlier gene 
expression information and genomic annotation as priors122. And both priors are evaluated 
as an average across tissues, instead of considering individual tissue. My categorizing 
system emphasizes that the intolerance of promoter and depletion of rare regulatory 
variants of genes can be shared among tissues, and also be observed in single tissues. This 
system can be served as a resource to update existing gene constraint scores with tissue 
information, like pLI123, RVIS124,125. The next step will be focusing on the prediction of 
tissue-specific individual pathogenic rare variants by adding regulatory effects that result 
in extreme expression. The combination of both tissue and regulatory information will 
inevitably increase the accuracy and provide tissue functional information in genetic 
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